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Abstract
Aromatase inhibitors (AIs) are the most commonly used first-line endocrine treatment for
postmenopausal women with estrogen receptor-positive breast cancer. Significant
adverse drug reactions are associated with AIs, the most common being arthralgia. We
hypothesized that a comprehensive assessment of pharmacogenetic and clinical variables
that affect AI tolerability could improve AI selection and treatment for breast cancer
patients. We recruited 196 patients diagnosed with breast cancer initiating AI therapy at
the London Regional Cancer Program. Patients completed questionnaires regarding
arthralgia symptoms and provided blood samples at baseline, 2 months and 6 months
after AI initiation. Plasma letrozole drug concentration was measured by liquid
chromatography tandem-mass spectrometry (LC-MS/MS). DNA was extracted and used
for pharmacogenetic analysis. More than half of patients had increases in pain and
stiffness in their hands, shoulders, and arms, hips and knees. A LC-MS/MS analysis
demonstrated that plasma concentrations of letrozole were negatively associated with
body mass index (P = 0.0003) and positively associated with age (P = 0.0430). CYP2A6
genotype was significantly associated with letrozole levels (P < 0.0001), and increased
plasma letrozole levels were observed in patients with CYP2A6 reduced-function
genotypes. However, letrozole concentration level and CYP2A6 genotype were not
significantly associated with a change in pain score from baseline. Further
pharmacogenetic investigations revealed that four SNPs within the estrogen synthesis and
metabolism pathway, namely, CYP19A1 (rs4775936) and ESR1 (rs9322336, rs2234693,
rs930799), were associated with the development of arthralgia. CYP19A1 (rs4775936)
was also a significant predictor of discontinuation of drug. Finally, we found that a SNP
i

within the vitamin D pathway CYP27B1 (rs4646536) was associated with an increase in
pain in the hands, arms, and shoulders. Patients who had a vitamin D level of at least
50ng/ml were found to be four times less likely to develop AI arthralgia. Understanding
the impact of genes and drug levels on AI-induced arthralgia will help clinicians better
manage AI therapy. This work will facilitate personalized medicine for women with
breast cancer and advance understanding of endocrine biology.
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INTRODUCTION TO THE PATHOGENESIS AND
PHARMACOLOGICAL TREATMENT OF BREAST
CANCER

Section 1.6 to 1.10 reproduced from: Borrie AE, Kim RB. 2016. Molecular basis of
aromatase inhibitor associated arthralgia: known and potential candidate genes and
associated biomarkers. Expert Opin Drug Metab Toxicol 13(2):149-156
Reproduced with permission from the Expert Opinion on Drug Metabolism and
Toxicology, Volume
13 © 2016
by Taylor and Francis, http://
http://www.tandfonline.com/
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1.1 Introduction
Breast cancer is the most common cancer among Canadian women and second only to
lung cancer as a leading cause of death from cancer in Canadian women [1]. Breast
cancer is a heterogeneous group of diseases with subtypes that are characterized by
different clinical, molecular, genetic, histological, and prognostic characteristics [2].
Several different types of neoplasms arise from the cells in the breast. Most breast
cancers are adenocarcinonomas, which are tumours that originate in a gland cell. The
most common adenocarcinomas of the breast are ductal carcinoma, which begins in the
milk ducts, and lobular carcinoma, which starts in the lobules. Both men and women
have breast tissue but women have a much larger amount and a much higher risk for
breast cancer; less than 1% of all breast cancers occur in men [1].

1.2 Characterization of breast cancer
When a patient with breast cancer is first diagnosed, their disease is described by stage,
grade, and molecular subtype. Stage describes the anatomical extent of the tumour within
the body and is typically expressed as a number on a scale of 0 through IV. Stage is based
on the TNM (tumour, node, metastasis) system describing the size and extent of the
primary of the tumour, whether the cancer has spread to the regional lymph nodes, and
whether the cancer has spread to other areas of the body (metastasis). Grade is a score
based on visual assessment of cell morphology and architecture, and indicates how
quickly the cells are dividing and if the organization and morphology of the cells are
abnormal [3]. Typically, less differentiated and higher grade tumours are more
biologically aggressive.
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Breast cancer is also characterized by immunohistochemical and molecular subtypes, and
these subtypes have distinct pathological features as well as clinical implications.
Traditionally, breast cancers were classified as tumours that expressed the estrogen
receptor (ER-positive breast cancer) and those that did not (ER-negative breast cancer)
[4]. Early studies found that tumours in which the ER and progesterone receptor (PR)
were present were distinct from the more aggressive ER/PR-negative tumours that had a
less favourable prognosis. Human epidermal growth factor receptor 2 (HER2) is a protein
found to be overexpressed in approximately 15-30% of breast cancers and is associated
with more aggressive disease and poorer prognosis [5, 6]. ER, PR and HER2 can all be
measured by immunohistochemistry [7]. The four major molecular subtypes first
identified by Perou and colleagues are luminal A, luminal B, HER2-type, and basal-like
[8, 9]. Luminal A tumours are characterized by higher expression of ER (ER-positive),
normal expression of HER2 (HER2-negative), low histological grade, and are associated
with a favourable prognosis. Luminal A tumours have low levels of the protein Ki-67, a
cellular marker for proliferation. Approximately 50-70% of all breast cancers are luminal
A tumours, making it the most common subtype [10]. Luminal B tumours make up
approximately 10-20% of breast cancers and this subtype is characterized by high
expression of ER, high levels of Ki-67, normal or high expression of HER2, as well as
intermediate histological grade and larger tumour size. Luminal B tumours tend to have a
relatively good prognosis, though not as favourable as luminal A tumours [10]. HER2type tumours are characterized by intermediate to high histological grade, are ERnegative, predominately HER2-positive, and account for 15-20% of breast cancers.
HER2-type breast cancer has a poorer prognosis than the luminal subtypes. However,
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treatment with HER2 targeted therapies such as trastuzumab (Herceptin) may improve
outcomes [10, 11]. Basal-like tumours, which make up approximately 10-15% of all
breast cancers, tend to be ER, PR, and HER2-negative, and therefore, they are also
known as triple negative breast cancer. Basal-like tumours are the most aggressive form
of breast cancer and have the poorest prognosis [10]. These four subtypes were identified
based on gene expression patterns in tumor samples from patients with locally advanced
breast cancer and were confirmed using microarray expression profiling in a separate
patient cohort [8, 12]. Perou et al. also identified a fifth subtype, called normal-like,
which resembled the features of luminal A. However, this subtype was later hypothesized
to be a technical artifact thought to arise from contamination of samples with normal
mammary cells, and is not widely accepted as an official subtype [13]. Heterogeneous
expression of the estrogen, progesterone, and HER2 receptors has been observed among
different patients with breast cancer, as well as between matched samples from primary
tumours and their metastases. Patient treatment is planned based on factors such as
tumour size, grade, and molecular subtype. Table 1.1 summarizes the four major types of
breast cancer, their features, and their indicated treatments [14-16].
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Table 1.1 Summary of breast tumour molecular subtypes

6

1.3 Estrogen
Estrogen is an important hormone and signalling molecule best known for its role in
female reproduction, but is also involved in male reproduction as well as playing a
significant function in the immune, neuroendocrine, skeletal, and vascular systems of
both males and females [17]. Estrogen acts as a mediator in multiple physiological
pathways and has been implicated in the development and progression of diseases such as
cancer, cardiovascular disease, osteoporosis, obesity, and endometriosis [18]. It is well
established that estrogen is an essential mediator in the development of breast tissue in
females during puberty and pregnancy [19, 20]. Epithelial cells in the breast respond to
estrogen signalling through its receptor, estrogen receptor alpha (ERα), and progesterone
signalling through PR. Estrogen stimulates the development of tubules into the ductal
system of the breasts, the growth of stromal tissue, and the accumulation of adipose
tissue. Estrogen is a pivotal driver of ductal growth and elongation during breast
development [21, 22].
Estrogen also plays an important role in breast cancer; there is considerable evidence
linking estrogen exposure with an increased risk of breast cancer. While no clear
mechanism through which estrogen induces breast cancer has been found, one possible
pathway is that of estrogen binding to ERα and inducing breast cell proliferation through
its direct and indirect actions on the enhanced production of growth factors [23]. A longer
duration of estrogen exposure, through early menarche and late menopause, is known to
lead to an increased risk of developing breast cancer [24].
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There are two major types of estrogen in postmenopausal women – estrone and estradiol.
Aromatase is an enzyme transcribed from the CYP19A1 gene that catalyzes estrogen
biosynthesis through the conversion of testosterone to estradiol and androstenedione to
estrone (Figure 1.1) [25, 26]. While estrogen is produced in the ovaries and adipose tissue
in premenopausal women, among postmenopausal women, adipose tissue is considered to
be the major source of estrogen synthesis[27]. Aromatase is expressed across multiple
human tissues including the ovaries, testes, adipose tissue, brain, muscle, skin fibroblasts
and osteoblasts of bone[28]. Therefore, use of aromatase inhibitors (AIs) results in
reduced formation of estrogens, thus lowering the amount of circulating estrogens and
thereby reduce ER-dependent cellular proliferation [29].
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1.4 Estrogen receptor
Estrogenic effects largely occur as a consequence of the activation of the two forms of
the ER, ERα and ERβ, upon binding with estrogen [30]. When a tumour is classified as
ER+ or ER-, it is the ERα that is present. ERα, encoded by the ESR1 gene, is activated by
estrogen binding [31], resulting in increased cell proliferation. Thus, expression of ERα
has been proposed as a possible mechanism for the initiation of breast cancer. The ERβ is
encoded by the ESR2 gene, but its role is less well understood [32]. Both ERα and ERβ
are widely expressed across many tissues. Figure 1.2 illustrates how estrogen acts as a
ligand to initiate estrogen receptor signaling, which regulates the expression of multiple
target genes [17].
Though estrogen effects are primarily mediated by ERα and ERβ, a G protein estrogen
receptor, (GPER) also mediates estrogen action in both normal and malignant cells [33].
GPER, also known as GPR30, is localized on the cell membrane and the endoplasmic
reticulum. It is expressed in a variety of tissues including the breast and the blood vessel
endothelium, and is involved in regulating breast development and vasodilation [34, 35].
Until 2005, GPER was considered an orphan receptor, however recent studies have
shown that its’ stimulation may play an important role in cell proliferation and cancer cell
invasion [36]. Currently there are no large clinical studies evaluating GPER expression in
ER-positive breast cancer, though this could be an area that is addressed in the future.
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Figure 1.2 Signalling of the estrogen receptor in breast cancer
1) Estrogen binds with high affinity and 2) changes the shape of the receptor. 3) Specific
sites are activated, and in this state, the receptors can combine to form dimers. 4) The
dimers translocate into the nucleus and 5) bind to discrete DNA sequences called
estrogen response elements (ERE). Co-activators are recruited, and this results in RNA
polymerase.
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1.5 Breast cancer in postmenopausal women
Approximately 80% of breast cancers occur in postmenopausal women. While
menopause is not a risk factor for breast cancer, the risk of developing cancer increases
with age [37]. Obesity is also associated with a significantly elevated risk of breast cancer
[38] and a poor prognosis among postmenopausal breast cancer patients [39, 40]. In
postmenopausal women, estrogen is no longer produced by the ovaries but is still
synthesized in many tissues, with adipose tissue becoming the main source of estrogen.
Other estrogen-producing tissues include skin, muscle, and healthy and malignant breast
tissue [26]. Increased fat tissue leads to higher estrogen levels, which can increase breast
cancer risk [24].

1.6 Breast Cancer Treatment
Breast cancer treatment is prescribed by an oncologist and is based on the molecular
subtype, size, node status, and grade of the tumour, as well as the age, sex, and
menopausal status of the patient [41]. Surgery and radiation therapy are localized
regional treatments used to target the cancer at the tumour site. Surgery involves the
removal of the cancer tissues and a small amount of healthy tissue surrounding the
tumour, while radiation therapy ablates cancer cells using high-energy radiation. Breast
cancer may also be treated with systematic treatments that include chemotherapy,
endocrine therapy, and biological therapy [41].
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1.6.1

Endocrine therapy

Over a century ago, the discovery that ovarian ablation may precipitate tumour regression
in premenopausal women marked the beginning of endocrine-based treatment of breast
cancer [42]. The approval of tamoxifen, a selective estrogen receptor modulator, for
breast cancer in 1977 led to a marked improvement in survival for ER-positive breast
cancer. The next advance in endocrine therapy came with the aromatase inhibitors (AIs),
letrozole, anastrozole, and exemestane, whose chemical structures are depicted in Figure
1.3. These therapies improved 10-year survival rates and decreased the risk of disease
relapse in postmenopausal women with breast cancer over treatment with tamoxifen [43,
44]. Today, endocrine-based therapy is prescribed to women with ER/PR-positive breast
cancer based on their menopausal status and cancer relapse risk. Endocrine therapy slows
or stops cancer growth by disrupting the signalling of ERα in the case of tamoxifen, or by
reducing the available estrogen to cancer cells in the case of AIs. Tamoxifen is primarily
used to treat pre-menopausal women, although it can also be used to treat postmenopausal women, and AIs are used to treat post-menopausal women. Because AIs
interfere with the conversion of androgens into estrogens in peripheral tissues (skin,
muscle, fat, and benign and malignant breast tissue), they are only capable of lowering
estrogen production outside of the ovaries and are therefore only prescribed to postmenopausal women [26, 45].
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Figure 1.3 Chemical structures of the aromatase inhibitors
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1.6.2

Aromatase inhibitors

Currently, letrozole, anastrozole, and exemestane, are the most commonly prescribed AIs
for the treatment of women with ER+ breast cancer. Lowering estrogen causes the
tumour growth to be reduced, and limits disease progression and recurrence [46-48]. AIs
block the activity of aromatase by binding to the enzyme either reversibly, as in the case
of letrozole and anastrozole, or irreversibly, as in the case of exemestane. Letrozole and
anastrozole are known to competitively bind to the AI substrate-binding site, prevent
binding of androgens, thus limiting the catalytic conversion of androgens to estrogen.
Exemestane binds irreversibly to the AI active site to inactivate the enzyme commonly
referred to as “suicide inhibition” [49]. All three AIs potently reduce estrogen below the
level that can be detected using most of the current clinical assays [50]. Letrozole inhibits
approximately 99% of estrogen biosynthesis, while anastrozole has an inhibition rate of
97%, and exemestane inhibits 98% of estrogen biosynthesis [51]. It should be noted that
AIs are typically prescribed for 5 years, usually after adjuvant chemotherapy, surgery,
and/or radiation, although it can be prescribed as a monotherapy for early stages of breast
cancer. AIs may also be prescribed for 2-3 years following 2-3 years of tamoxifen
therapy [46-48].

While aromatase inhibitors greatly reduce

estrogen levels,

dihydrotestosterone, total testosterone, androstenedione, DHEA, or free androgen index
levels are not affected [52].
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1.6.2.1

Letrozole

Letrozole, also known by the trade name Femara, is a non-steroidal aromatase inhibitor
that binds reversibly to the aromatase enzyme and blocks the conversion of androgen to
estrogen via competitive inhibition. It is prescribed as a standard oral dose of 2.5mg daily
for five years, and its absorption is not affected by food [53]. It has a terminal half-life of
48h and steady-state plasma concentration is reached in 2-6 weeks [53] although some
studies have shown that it may take up to 8 weeks to reach steady-state concentration
[54]. Maximal estrogen suppression of greater than 90% is reached within 14 days of the
drug start date [55].

1.6.2.2

Anastrozole

Anastrozole, also known as Arimidex, is a non-steroidal aromatase inhibitor, which like
letrozole, reversibly binds to the aromatase enzyme and blocks estrogen production
through competitive inhibition [56]. Anastrozole has a standard daily oral dose of 1mg
for a total treatment duration of five years. The terminal half-life of anastrozole is 46
hours, and plasma concentrations reach steady-state levels at approximately 7 days [56].
Maximal estrogen suppression of greater than 90% is achieved within 2-4 days of daily
1mg dosage [57].
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1.6.2.3

Exemestane

Exemestane, also known by the brand name Aromasin, is a steroidal aromatase inhibitor
structurally related to androstenedione, and it binds to the active site of aromatase
enzyme irreversibly, resulting in inactivation by suicide inhibition. Exemestane is given
at a daily oral dose of 25mg for five years, has a terminal half-life of 24 hours, and
reaches steady-state concentration level by 7 days [58, 59].

1.6.3

Adverse drug reactions associated with AIs

Meta-analysis and cross-trial comparisons of the three AIs have shown that they have
similar adverse drug reaction (ADR) profiles across the drug class [60, 61]. The most
common ADRs are arthralgia and joint symptoms, which affect up to 50% of patients
[62, 63]. Significantly, up to 30% of patients on AIs will discontinue their use due to
ADRs, and 75% report the cause of discontinuation is arthralgia [64]. Other common
ADRs include hot flashes and night sweats, fatigue, loss of bone mineral density, loss of
sex drive, and vaginal dryness or itching. Less frequent ADRs include thinning of the
hair, increased blood pressure, increased cholesterol, and cognitive effects such as mood
swings and depression. Due to the androgenic structure of exemestane, it is known to
give rise to hormonal effects apart from the decrease in estrogen production and is
sometimes associated with weight gain and acne [58]. Letrozole and anastrozole have a
non-steroidal molecular structure and therefore do not have the same androgenic,
progestogenic, or estrogenic ADRs as exemestane [65].
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1.6.4

Aromatase inhibitor induced arthralgia

AIs are effective for treating breast cancer, but they may have unwanted musculoskeletal
effects, including joint pain (arthralgia) and muscle pain (myalgia) [62, 66, 67]. This
adverse effect is often referred to as AI-associated musculoskeletal syndrome. Arthralgia
and myalgia are widely regarded as the most common and pervasive adverse drug
reactions reported by patients treated with AIs. AI-induced arthralgia presents in patients
with joint pain, typically affecting the wrists, hands, shoulders, hips and knees [62]. AIinduced arthralgia often compromises quality of life and lead to non-adherence of the
drug. Other less common adverse drug reactions include thinning of the bones or
osteoporosis, vaginal dryness, vaginal bleeding, and loss of libido [68-70]. Patients who
experience AI-induced arthralgia find that these symptoms typically appear within the
first month of drug initiation and worsen in the second and third months of drug use [71].
AI-induced arthralgia is resistant to treatment with NSAIDs, opioids, and other pain
medications [72].
It is difficult to pinpoint the exact prevalence of AI-induced arthralgia for a variety of
reasons. Within the literature that describes AI-induced arthralgia, there is not a
consistent definition relating to severity or types of pain. Furthermore, the largest clinical
trials of AIs were not designed to capture and examine arthralgia. In a 5-year study that
compared anastrozole to tamoxifen, the prevalence of arthralgia in breast cancer patients
on anastrozole was 35% [73]. A large randomized study of more than 4,000 patients,
which compared patients on exemestane to patients on tamoxifen, reported that the
prevalence of arthralgia was only 5% in patients taking exemestane [46]. However,

18

another similarly powered study of exemestane in post-menopausal women found that
30% of patients had arthralgia [74]. The rates of arthralgia vary greatly when measured
by patient self-reporting. However, studies that were specifically designed to measure the
prevalence of AI-induced arthralgia, found the rates are consistently higher, and closer to
50% of patients. One study of 200 women on AIs utilized a 25-item questionnaire
designed to assess joint symptoms and found that 47% of women developed AI-related
joint pain and 44% developed AI-related stiffness [62].
Currently, the mechanism that underlies AI-induced arthralgia is largely unknown,
although there is a growing body of literature that suggests there may be multiple
intersecting mechanisms. Patient variability in AI metabolism and drug levels, the rate of
estrogen decline during AI treatment, vitamin D deficiency, and increased muscle and
joint inflammation have all been associated with arthralgia (Table 1.2). Links between
these factors suggest an interplay of complex mechanisms (Figure 1.4).
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Figure 1.4 An overview of proposed mechanisms for AI arthralgia
Associated genes are depicted in grey. Associated biomarkers are depicted in black.
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Table 1.2 Gene variants involved in AI arthralgia
Select variants and variant effects within estrogen metabolism genes
ESR1
rs2234693
upstream SNP
In vivo
rs9340799
intronic SNP
In vivo
rs9322336
intronic SNP
In vivo
CYP17A1
rs4919686
a SNP
In vivo
rs4919683
a SNP
In vivo
rs4919687
a SNP
In vivo
rs3781287
a SNP
In vivo
rs10786712
a SNP
In vivo
rs6163
synonymous SNP
In vivo
rs743572
a SNP
In vivo
CYP19A1
rs60271534
repeat polymorphism (intron 4)
In vivo
Haplotype M_3_5
haplotype of 14 SNPs
In vivo
rs4775936
intronic SNP
In vivo

Currently unknown
Currently unknown
Currently unknown

[85]
[85]
[86]

Currently unknown
Currently unknown
Currently unknown
Currently unknown
Currently unknown
Currently unknown
Currently unknown

[79]
[79]
[79]
[79]
[79]
[79]
[79]

Currently unknown
Currently unknown
Currently unknown

[81]
[82]
[79]

Select variants and variant effects within genes which regulate inflammation
OPG
rs2073618
TCL1A
rs11849538

a SNP

In vivo

Currently unknown

a functional SNP

In vivo and
Creates an estrogen response element
in vitro
studies
Select variants and variant effects within aromatase inhibitor metabolism genes
CYP2A6
CYP2A6*2
a SNP
In vivo
results in less than 40% CYP2A6
(rs1801272)
activity
CYP2A6*4
a whole deletion of gene
In vivo
results in no CYP2A6 activity
CYP2A6*9
a SNP
In vivo
results in 40-50% CYP2A6 activity
(rs28399433)
CYP2A6*12
a translocation
In vivo
results in 40-50% CYP2A6 activity
CYP3A4
CYP3A4*22
a SNP
In vivo and
associated with low CYP3A4 activity
(rs35599367)
in vitro
studies
CYP3A5
CYP3A5 *3
a SNP
In vivo and
associated with lower clearance of drugs
(rs35599367)
in vitro
metabolized by the gene product of
studies
CYP3A5
UGT2B17
Deletion
a whole deletion of gene
In vivo and
decreases 17-hydroexemestane
in vitro
glucuronidation process by 14 times,
studies
effecting both metabolism and excretion
of the active metabolite

[78, 83]
[92, 93]

[99]
[99]
[99]
[99]
[104]

[105]

[106]

Select variants and variant effects within Vitamin D metabolism/pathway genes
VDR
rs11568820

CYP27B1
rs4646536
rs10877012

a SNP in a cdx-2-binding site in
the VDR promoter and can
modulate gene expression levels

In vivo and
in vitro
studies

in vitro study that rs11568820 alleles
have different transcriptional activities

[79]

SNP in intronic region
SNP in promoter region

In vivo
In vivo

Currently unknown
Currently unknown

[79]
[79]
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1.7 Estrogen deprivation and metabolism
As early as 1925, loss of estrogen in women was noted to link with arthralgia [75]. There
is also evidence to suggest that the sudden decline in estrogen levels, rather than simply a
low estrogen state, stimulates arthralgia. In a large study of over 2000 women, 41% of
peri-menopausal women presented with increased joint pain and stiffness, while only
25% of pre-menopausal women and 29% of post-menopausal women had these same
symptoms [76]. Furthermore, the Women’s Health Initiative found that estrogen
replacement therapy improves arthralgia and joint health in post-menopausal women
[77]. A study of 420 post-menopausal breast cancer patients, all on AIs, found that mean
estradiol levels were significantly lower in patients with AI arthralgia than in patients
without AI arthralgia [78].

1.7.1

Estrogen synthesis (CYP17A1 and CYP19A1)

CYP17A1 (also known as 17α-hydroxylase) and CYP19A1 (also known as aromatase)
are the key enzymes that both play pivotal roles in estrogen synthesis. Specifically,
CYP17A1 adds a hydroxyl group to both pregnenolone and progesterone, and then
further converts them to androstenedione. Aromatase catalyzes the final step of
converting androstenedione to estrone (Figure 1.1).
A clinical study of postmenopausal women with breast cancer on AIs found an
association between AI arthralgia and several single nucleotide polymorphisms (SNPs) in
CYP17A1 (rs4919686, rs4919683, rs4919687, rs3781287, rs10786712, rs6163, rs743572)
[79].
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CYP19A1 is highly polymorphic, with more than 88 known SNPs, including at least 4
non-synonymous SNPs [80]. Variation in the CYP19A1 gene, specifically a
tetranucleotide repeat polymorphism in intron 4 (rs60271534), has been shown to alter
levels of estrone and estradiol in patients on AI therapy. In the same study, patients who
carry at least one 8-repeat allele had a lower risk of developing AI arthralgia [81].
Another study which focused on haplotypes within CYP19A1 found that AI arthralgia
was significantly and strongly associated with haplotype M_3_5, which contained the
following 14 SNPs: rs12148604, rs4646, rs10046, rs700519, rs4324076, rs700518,
rs3759811, rs727479, rs4775936, rs10459592, rs767199, rs10519297, rs1062033,
rs2008691, rs1008805, and rs17523527 [82]. However, a subsequent study of 154
patients on AIs failed to replicate the association with AI arthralgia when they tested 6
SNPs from haplotype M_3_5 (rs10046, rs700519, rs700518, rs727479, rs4775936,
rs10459592) [83]. When Garcia-Giralt et al. tested two of the SNPs included in haplotype
M_3_5 (rs4775936 and rs1062033) in a study of 343 postmenopausal women on AIs,
they did not find that either SNP alone predicted AI arthralgia. However, one of the
haplotype M_3_5 SNPs, rs4775936, was associated with worsening pain [79].

1.7.2

Estrogen receptor 1 (ESR1)

Estrogen receptor alpha (ERα) is encoded by ESR1 and is an important member of a
nuclear hormone receptor superfamily. ERα is responsible for mediating the effects of
estrogens and because it is expressed in ER-positive breast tumours and drives
proliferation of breast cancer cells, thus it is the primary target of endocrine therapies
[84]. A clinical study of patients on AI therapy found that two SNPs in the ESR1 gene

23

(rs2234693 and rs9340799) were associated with AI arthralgia [85]. [85]. rs2234693 is a
SNP located upstream of ESR1 and is also known as the -397T>C variation. rs9340799 is
located in an intronic region of ESR1. A large study of patients on letrozole and
exemestane demonstrated an association between ESR1 SNP rs9322336 and
discontinuation of AI therapy due to musculoskeletal toxicity; however, this effect was
only present for the patients on exemestane [86]. Further replication and functional
validation of these 3 SNPs are needed.

1.8 Potential role of Inflammation in AI-arthralgia
Arthralgia is often caused by inflammation within the muscles and joints, and
inflammatory cytokines are linked to estrogen levels in the body. Specifically, higher
levels of estrogen suppress inflammatory cytokine production, while lower estrogen
levels increase their production [87]. Specific inflammatory cytokines such as tumor
necrosis factor-α (TNF-α), interleukin-1 (IL-1) have been detected in peri-menopausal
women and found at higher concentrations in the synovial fluid of joints, which may
contribute to inflammation and pain [88]. As AIs suddenly and markedly deplete estrogen
in treated patients, this rapid lowering of estrogen may be part of the mechanism of AIinduced arthralgia.
However, the evidence to support a direct effect of lower estrogen levels to arthralgia is
somewhat conflicting. A recent study of 30 cases with AI arthralgia and 22 controls
without AI arthralgia measured changes in serum concentrations of inflammatory
molecules, including IL-1, interleukin-6 (IL-6), and TNF-α [89]. Contrary to previous
reports, this study found no statistically significant differences in serum concentrations
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for any of the inflammatory biomarker between cases and controls. In fact, for 6 of 36
factors, baseline measurements of serum concentration levels were significantly lower in
cases than controls. One of the limitations of this study was that inflammatory molecules
were measured systemically, whereas inflammation may be occurring locally at the
joints. A study that used magnetic resonance imaging was able to demonstrate
tenosynovial and articular changes in patients who developed AI arthralgia in their hands
and wrists, suggesting active inflammation in the actual joints or tissues around the joint
[90].

1.8.1

Osteoprotegerin and RANKL in AI arthralgia

Osteoprotegerin is a cytokine receptor and a member of the TNF receptor superfamily.
Recent studies have found an association between a SNP (rs2073618) in osteoprotegerin
(OPG) gene and AI arthralgia [78, 83]. OPG is a receptor for a ligand called receptor
activator of nuclear factor kappa-B ligand (RANKL). When OPG binds to RANKL, it
prevents nuclear factor kappa B (NF-κB) activation, which is a key transcription factor
for immune-related genes, and a known regulator of inflammatory response [91].

1.8.2

T-cell leukemia 1A (TCL1A)

Variation in the TCL1A gene was identified to be associated with AI-arthralgia in a
genome-wide association study (GWAS) that included 293 cases with AI-arthralgia and
585 controls. Four SNPs close to TCL1A were found to be the most significantly
associated with AI arthralgia (P = 2.23E-06 to 6.67E-07) [92]. The same research group
conducted functional validation studies and found that one SNP in particular
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(rs11849538) created an estrogen response element (ERE). This finding is significant
because the ERE demonstrated estrogen receptor binding and increased estrogen
induction of the TCL1A gene for the variant genotype. These SNPs were also found to
regulate the expression of cytokines and cytokine receptors in an estrogen-dependent
manner [93]. These findings link not only inflammation pathways but also estrogen
signaling to AI-arthralgia.

1.9 Pharmacogenetics of aromatase inhibitors
Cytochrome P450 (CYP) enzymes are known to be important to the metabolism of
endogenous as well as xenobiotic compounds. Certain CYP enzymes, including the
aromatase CYP19A1, have a limited spectrum of endogenous substrates such as
androgen. However, other members of the CYP family of enzymes, including those in the
CYP2 and 3 families are involved in the metabolism of xenobiotics. We know CYP3A4
and CYP2A6 have been shown to be responsible for metabolizing the currently available
AIs. Although all patients on AIs take the same daily dose of each of their prescribed
drugs (2.5mg for letrozole, 1mg for anastrozole, and 25mg for exemestane), there is
significant interpatient variability in circulating drug concentration [94-99]. A study that
examined the drug plasma levels of patients on letrozole found that there was more than a
12-fold variation in drug concentration when corrected for time of the patient’s last dose
[99]. Similarly, there is a greater than 10-fold variability in plasma concentration of
anastrozole and exemestane [97]. Thus it is likely variation in the expression and function
of CYP3A4 or CYP2A6 likely impact attained AI levels, and thereby increase the risk of
AI-induced arthralgia. Interestingly, switching from one aromatase inhibitor to another in
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some cases seem to resolve AI arthralgia. One study of patients on anastrozole with AI
arthralgia demonstrated that 71.5% of patients who switched to letrozole were able to
tolerate therapy on the second AI [100]. This establishes that patients may experience AI
arthralgia with one AI, but not another, indicating that inter-patient differences in
metabolism may play a role, since as noted previously, all of the current AIs are potent
inhibitors of their target, CYP19A1. Therefore, some of the variation in attained AI levels
may relate to pharmacogenetic variation [94-97].

1.9.1

Letrozole pharmacogenetics

Letrozole is metabolized to its pharmacologically inactive secondary metabolite, carbinol
or 4,4-methanol-bisbenzonitrile, by the enzyme CYP2A6 [94, 95]. CYP2A6 is a highly
polymorphic enzyme, however, most SNPs that have been detected are extremely rare,
thus unlikely to account for the commonly observed arthralgia during letrozole use.
However, there are several relatively commonly occurring genetic variations in CYP2A6.
Such variations include CYP2A6*2, a SNP that results in less than 40% activity,
CYP2A6*4, a deletion of the gene resulting in no activity, CYP2A6*9, a SNP that results
in 40-50% activity, and CYP2A6*12, a translocation which results in 40-50% activity
[101-103]. Letrozole plasma levels were significantly linked to whether a patient was a
normal, intermediate, or slow metabolizer of letrozole in relation to their CYP2A6
genotype. Intermediate and slow metabolizers of CYP2A6 consistently had the highest
levels of letrozole [99].
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1.9.2

Anastrozole pharmacogenetics

Anastrozole is predominantly oxidized in the liver to hydroxyanastrozole by CYP3A4
and CYP3A5 [96, 97]. For anastrozole, previous studies have shown a range of plasma
concentration levels of approximately 10ng/ml to 120ng/ml [97]. CYP3A4*22 is a
relatively recently identified SNP associated with low CYP3A4 activity [104]. For
CYP3A5, 80% of Caucasians are homozygous for the complete loss of function allele
CYP3A5*3 [105]. Accordingly, a subset of patients would be predicted to more rapidly
metabolize drugs such as anastrozole. Note that Phase II enzymes are also involved in the
further conversion of hydroxyanastrozole to its glucuronide form through the action of
UGT1A4 and, less commonly, by UGT2B7 and UGT1A3 [97].

1.9.3

Exemestane pharmacogenetics

Exemestane is metabolized by two main pathways – it is reduced to its biologically active
metabolite, 17-hydroexemestane by CYP4A11, CYP1A1, and CYP1A2, and it is
oxidized to 6-hydroxymethylexemestane by CYP3A4, CYP3A5, CYP2C8 [96]. 17hydroexemestane is further metabolized by glucuronidation to exemestane-17-Oglucuronide predominantly by UGT2B17. In vitro studies have shown that an entire gene
deletion polymorphism of UGT2B17 decreases 17-hydroexemestane glucuronidation
processes, affecting both metabolism and excretion of the active metabolite [106]. A
recent paper validated this in humans by demonstrating that a UGT2B17 gene deletion
polymorphism significantly alters 17-hydroexemestane pharmacokinetic profile [107].
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1.10 Vitamin D deficiency in AI-arthralgia
Vitamin D also appears to play a role in the development of AI-induced arthralgia.
Vitamin D deficiency and insufficiency are common in post-menopausal women
initiating adjuvant AI. Several studies have demonstrated that patients who have
insufficient or deficient levels of vitamin D are more likely to experience arthralgia
during AI therapy. One study found that patients on AIs with musculoskeletal symptoms
were more likely to have deficient vitamin D baseline levels when compared to
asymptomatic patients [108]. Another study found that vitamin D levels were closely
related to the intensity of the arthralgia, with the most severely affected patients having
the lowest vitamin D levels [109]. A double-blind placebo-controlled randomized was
performed with 60 women who were taking anastrozole to establish whether vitamin D
supplementation could improve the symptoms AI-induced arthralgia. The study found
that weekly high dose vitamin D significantly improved AI-induced arthralgia [110]. Like
estrogen, vitamin D has been linked with inflammation signaling pathways, which
suggests a potential mechanistic role of vitamin D in AI-induced arthralgia [111].
However, more research is needed to more fully clarify how vitamin D related factors
interact with AIs to in terms of joint pain.

1.10.1

The role of CYP27B1 in vitamin D metabolism

CYP27B1 encodes 1-α-hydroxylase that catalyzes the hydroxylation of 25(OH)D or
calcidiol to the bioactive form 1,25(OH)2D or calcitriol. Estrogen is known to increase
the activity of 1-α-hydroxylase, thereby increasing the conversion of calcidiol to calcitriol
[72]. Hormone replacement therapy in postmenopausal women has been found to
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increase circulating levels of calcitriol and is known to support musculoskeletal health
[112]. An AI-induced decrease in estrogen levels may result in reduced activation of 1-α
hydroxylase and therefore a reduction in circulating calcitriol levels. Therefore it is
possible that decreased calcitriol may be contributing to AI arthralgia.
The potential role of calcitriol in AI arthralgia is supported in a study that identified two
SNPs in CYP27B1 (rs4646536 and rs10877012) which were associated with AI arthralgia
and one SNP in CYP27B1 associated with discontinuation of therapy (rs4646536) [79].
Interestingly, in this same study, the authors reported an interaction between CYP27B1
and CYP17A1. Patients who carried risk alleles for both genes had the worst clinical
response, with the greatest degree of increased arthralgia at 3 months and 1 year of
follow-up on AIs [79].

1.10.2

Vitamin D receptor (VDR)

The vitamin D receptor (VDR) or calcitriol receptor, encoded by the VDR gene, binds to
calcitriol and mediates its biological activity. VDR is widely expressed in the human
body and is responsible for regulating the gene expression of a variety of genes involved
in inflammation, mineral homeostasis, and skeletal health, as well as renal and
cardiovascular protection [113]. Estrogen is known to increase the activity of vitamin D
receptor [72]. One SNP in VDR (rs11568820) has been shown to be significantly
associated with AI arthralgia [79]. The SNP rs11568820 is located in a cdx-2-binding site
of the VDR promoter. In vitro studies have shown that the presence of this SNP effect
VDR transcriptional activity and thereby modulate gene expression levels, and of
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potential functional relevance to AI arthralgia [114]. This Cdx-2 SNP has also been
previously associated with an increased risk of cancer, particularly ovarian cancer [115].

1.11 Specific Aims and Hypotheses
1.11.1

Specific Aim 1

Document and quantify adverse drug reactions in patients with ER-positive breast
cancer on AIs. Based on the allele frequency of the genetic variants to be examined, we
recruited 200 patients from the London Regional Cancer Program. Clinical variables and
adverse drug reaction history were recorded.
Inclusion criteria for enrollment into the study included:
1) Postmenopausal women with a diagnosis of stage I to stage III estrogen-receptor
positive breast cancer.
2) Patients who had completed their initial treatment of surgery, radiation therapy,
IV chemotherapy regimens or tamoxifen therapy.
3) Patients who had been prescribed aromatase inhibitor treatment (letrozole,
anastrozole, exemestane) but had not yet started their medication.
Exclusion criteria for enrollment into the study included:
1) Patients who were unable to understand written or spoken English.
2) Patients who had a psychiatric history or disability that could affect their ability to
give informed consent.
Patients recommended for initiation of AI therapy were identified by their treating
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oncologist and were approached by our research team at their clinic appointments. Once
informed consent was obtained, the patients were asked to complete two validated
questionnaires regarding musculoskeletal side effects. The questionnaires were
administered to patients on three separate occasions; prior to AI therapy initiation,
approximately 6 weeks post-initiation and 6 months post-initiation. The administration
of questionnaires coincided with the patient's clinic visits to avoid additional
appointments for the patients. An overview of the study is shown in Figure 1.5.
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Figure 1.5 Overview of study design
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The first questionnaire was the Australian/Canadian Osteoarthritis Hand Index
(AUSCAN), version 3.1, which is a 15-item questionnaire that assesses pain, stiffness,
and physical functioning of the hands. The AUSCAN is a reliable measure of clinical
outcomes and has validated age and gender-specific normative values [98, 116]. The
questionnaire contains three subscales (pain, stiffness, and physical functioning); each is
scored as the sum of the items on the subscale. An example of the AUSCAN
questionnaire is attached as Appendix C. The second questionnaire that was administered
was the Western Ontario and McMaster Osteoarthritis Index (WOMAC), version 3.1.
This clinical tool assesses pain, stiffness, and physical functioning in the lower
extremities, knees, and hips. The questionnaire has 24 items and validated age- and
gender-specific normative values are available [117]. The WOMAC consists of three
subscales (pain, stiffness, and physical functioning), each scored as the sum of the items
on that subscale. An example of the WOMAC questionnaire is attached as Appendix D.
An important element of this aim was to evaluate whether there are changes in the
occurrence of adverse drug reactions over time. In order to test whether AI-induced
arthralgia increase over time, I administered the AUSCAN and WOMAC questionnaires
and measured changes over 6 months. AI-induced arthralgia symptoms have been
reported to typically appear in the first 6 months of treatment. The first symptoms tend to
appear within the first month of drug initiation, and intensifying in the second and third
months of drug use [71]. Because AI-induced arthralgia have not been known to emerge
or be reported for the first time after the 6 month point, we chose our patient follow-up
times to be 6 weeks and 6 months. Oncologists at the LRCP typically see patients in
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clinic at 6 weeks and 6 months following initiation of therapy, and I collected blood
samples and administered two questionnaires at patients’ regular appointments.

1.11.2

Specific Aim 2

Measure drug levels of AIs and vitamin D levels in breast cancer patients to
determine the range of AI levels in response to standard doses. By measuring drug
concentration levels of patients on AIs, we were able to determine whether some patients
were outside the therapeutic range, either sub-therapeutic which may affect efficacy or a
higher than normal drug concentration level which may cause toxicity. Blood samples
were be obtained for drug level analysis by liquid chromatography/mass spectrometry
and vitamin D level analysis at 6 weeks and 6 months post-initiation of therapy. Drug
concentration level analysis of the aromatase inhibitors was achieved by using liquid
chromatography/mass spectrometry, as described in Chapter 4.

1.11.3

Specific Aim 3

Determine the genotype of relevant genes in the metabolic pathway of AIs including
CYP3A4, CYP3A5, and CYP2A6. Determine the genotype of other potential
arthralgia biomarkers, including the estrogen synthesis pathway (ESR1, CYP19A1),
the inflammation pathway (OPG, RANKL, TLC1A), and the vitamin D pathway
(VDR and CYP27B1). Blood samples were obtained for genotyping by TaqMan SNP
assays. Statistical modeling on our patient cohort was used to determine important
genetic predictors of AI efficacy and adverse drug reaction risk.
A thorough review of the current literature has revealed which genes are known to
contribute to the metabolism of AIs. The gene product of CYP2A6 metabolizes letrozole
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to its pharmacologically inactive secondary metabolite called carbinol or 4,4-methanolbisbenzonitrile [94, 95]. There are more than 50 different types of variation in CYP2A6,
however most SNPs that have been detected are extremely rare, and may not affect the
activity of CYP2A6. Therefore, I genotyped patients using the 4 most common star-alleles
found within our target population. These included CYP2A6*2, a SNP that results in less
than 40% activity, CYP2A6*4, a deletion of the gene resulting in no activity, CYP2A6*9,
a SNP that results in 40-50% activity, and CYP2A6*12, a translocation which results in
40-50% activity [101-103]. As described in Chapters 2, 5, and 6, SNPs from estrogen
synthesis pathway (ESR1, CYP17A1, CYP19A1), the inflammation pathway (OPG,
RANKL, TLC1A), and the vitamin D pathway (VDR and CYP27B1) were chosen based on
previous literature in this field.

1.11.4

Hypotheses

The variability within genes and pharmacokinetics of the AIs in patients with breast
cancer explains much of the differences in efficacy and adverse drug reactions between
individuals. We hypothesized that polymorphisms in CYP2A6 and CYP3A4/5 are
associated with altered plasma drug levels and adverse drug reactions. Variation in other
arthralgia biomarker genes (ESR1, CYP19A1, OPG, TLC1A, RANKL, VDR, and
CYP27B1) may explain arthralgia through additional pathways. Understanding the
variability can also support the prediction of optimal drug levels, thereby improving
efficacy and safety of outcomes in breast cancer patients.
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1.12 Outline of thesis
The analyses in this thesis have been done on a population of 200 postmenopausal
women with breast cancer who were initiated on two different aromatase inhibitors,
letrozole and anastrozole. We did not have any patients enrolled on exemestane at our
site at the London Regional Cancer Program. Chapter 2 focuses on a sub-analysis of the
126 patients that were on letrozole. We selected these patients for a sub-analysis of the
total group to measure letrozole drug levels and genotypes related specifically to letrozole
metabolism. Because there were only 70 patients on anastrozole and no patients on
exemestane, we did not measure drug levels in these patients. Chapters 3 and 4 focus on
the full population of patients on AIs with the patients on letrozole and anastrozole
grouped together. Chapter 3 examines SNPs in the estrogen and inflammation pathways
and their association with AI induced arthralgia. Chapter 4 investigates the effect of
vitamin D on AI induced arthralgia, including both vitamin D levels and SNPs within the
vitamin D pathway.

1.13 Conclusion
Breast cancer is both the most common cancer and one of the leading causes of death in
women. Approximately 80% of breast cancer in postmenopausal women is ER-positive,
indicating that these tumours respond to estrogen, which promotes cancer cell
proliferation. AIs are the most commonly used first-line endocrine treatment for
postmenopausal women with ER-positive breast cancer, but AI activity varies widely
among patients. AIs, including letrozole, anastrozole, and exemestane, have been found
to deplete estrogen levels, reducing tumour growth and limiting disease progression and
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recurrence. Significant ADRs are associated with AIs, the most common being arthralgia.
Currently, the therapeutic response and occurrence of adverse effects with AIs for ERpositive breast cancers is largely unpredictable. Candidate genes and molecular
biomarkers associated with AI arthralgia offer valuable insight into the complex
mechanism of the adverse drug reaction. Additional research is needed to replicate and
validate candidate genes and biomarkers to develop utility in a clinical setting to prevent
the development of AI arthralgia. Understanding endocrine-based treatments and their
associated ADRs will help clinicians better manage AI therapy and deliver better care to
patients with breast cancer.
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LETROZOLE CONCENTRATION IS ASSOCIATED
WITH CYP2A6 VARIATION BUT NOT WITH
ARTHRALGIA IN PATIENTS WITH BREAST CANCER
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2.1 Introduction
Aromatase inhibitors (AIs) are the most commonly used first-line endocrine treatment for
postmenopausal women with estrogen receptor-positive (ER-positive) breast cancer [1].
Several adverse drug reactions (ADRs) are associated with AIs with the most common
being arthralgia; specifically, bilateral arthritic joint pain affecting the hands, elbows,
shoulders, hips, and knees [2]. AI-induced arthralgia affects up to 50% of patients and
20-30% of patients discontinue the medication due to intolerable symptoms [3]. Although
the etiology is currently unknown, several underlying mechanisms have been proposed,
including AI metabolism and pharmacogenetic factors [4].
Letrozole is one of three third-generation selective AIs and is prescribed as a
standard dose of 2.5mg daily for five years. The terminal half-life of letrozole is 48 hours,
and steady-state plasma concentration is reached in two to six weeks [5]. Letrozole is
metabolized primarily by cytochrome P450 2A6 (CYP2A6), an enzyme encoded by the
CYP2A6 gene, which is expressed mainly in the liver [6-8]. There are over 50 types of
CYP2A6 genetic alterations which effect its’ enzymatic activity. However, many of these
variants are rare, with minor allele frequencies of less than one percent. CYP2A6*1
represents the wild-type, or reference allele, and indicates normal CYP2A6 function. The
variant alleles most commonly found in Caucasian populations are CYP2A6*2,
CYP2A6*4, CYP2A6*9, and CYP2A6*12 [9]. CYP2A6*2 is a single nucleotide
polymorphism (SNP) that results in less than 40% enzyme activity. CYP2A6*4 represents
a deletion of the gene resulting in no activity [10]. CYP2A6*9 is a SNP within the TATA
box of the CYP2A6 promoter region that results in a 50-60% reduction in activity [11].
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CYP2A6*12 is a translocation which is caused by a crossover between the CYP2A6 and
CYP2A7 genes, resulting in a hybrid allele, and 40-50% activity [12].
Despite being prescribed as a standard dose, plasma concentrations of letrozole vary
greatly, ranging from 25ng/mL to 350ng/mL [7]. Several clinical factors have been found
to be associated with letrozole plasma concentration. Circulating concentrations of
letrozole are found to be negatively correlated with BMI and positively correlated with
age [7]. Furthermore, variation in CYP2A6 explains a large degree of the variability in
steady-state letrozole concentrations in patients with breast cancer [7] and healthy
postmenopausal women [13].
Though AI-induced arthralgia is widely recognized as the most common adverse
reaction for breast cancer patients taking letrozole, there is little consensus on how best to
measure these symptoms. A study by Swenson et al. compared the responsiveness of six
validated self-report questionnaires of musculoskeletal symptoms and two performancebased tests of physical function during treatment with AIs [14]. They found that the
instruments with the greatest sensitivity to changes over the first six months of AI use
were the Australian/Canadian Osteoarthritis hand index (AUSCAN) and the Western
Ontario and McMaster Osteoarthritis Index (WOMAC) [15]. Importantly, the physical
function subscales of the AUSCAN and WOMAC were the most sensitive to change and
able to effectively translate the measures of pain and stiffness to the impact on a patient’s
life.
While studies measuring letrozole concentration have established an association between
genotype and drug concentration, there is a lack of prospective studies that specifically
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examined the effect of plasma concentration and CYP2A6 genotype on the development
of letrozole-related arthralgia. We hypothesized that genetic polymorphisms in CYP2A6
were associated with altered letrozole plasma levels and arthralgia. In this study, we
prospectively examined the association of WOMAC and AUSCAN scores with
circulating levels of letrozole and CYP2A6 genotypes in postmenopausal women initiated
on letrozole therapy.

2.2 Materials and Methods
2.2.1

Study population

Postmenopausal breast cancer patients (n = 126) diagnosed with stages I-III ER-positive
breast cancer initiating letrozole therapy were enrolled at the London Regional Cancer
Program in London Ontario between April 2015 – December 2017. All study participants
provided written informed consent. This study was approved by the Research Ethics
Board at the University of Western Ontario.

2.2.2

Sample collection and storage

Blood samples were obtained from each patient at three time points: prior to letrozole
therapy initiation, approximately two months post-initiation, and six months postinitiation on 2.5mg of letrozole. The date and time of blood collection and last letrozole
dose were recorded and used to calculate the time (in hours) since the last dose. Plasma
was isolated from venous blood and stored at -80°C until analysis.
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2.2.3

Letrozole measurement

Steady-state plasma letrozole concentration was measured by liquid chromatographymass spectrometry (LC-MS/MS) using methods as described previously [16]. Letrozole
and the internal standard, letrozole-D4, were obtained from Toronto Research Chemicals
(Toronto, Ontario, Canada). Plasma samples (150 μL) were prepared with 10 μL of
internal standard and underwent solid phase extraction in BondElut C18 96-well plates
(Agilent Technologies, Santa Clara, California, USA). Upon injection into the liquid
chromatograph (Agilent 1200) the molecules were separated on a ZORBAX Eclipse
XDB-C18 column using a gradient elution with acetonitrile in 0.1% acetic acid. Standard
curves and quality control samples were prepared in drug-free plasma. The Thermo TSQ
Vantage mass spectrometer with heated electrospray ionization source was set in positive
mode for detection of letrozole and letrozole-D4 with transitions of 286.1→ 217 m/z and
290.1→ 221 m/z respectively.

2.2.4

Genotyping

DNA was extracted from whole EDTA blood using either the MagNA Pure Compact
instrument (Roche, Laval, Quebec, Canada) or the MagMaxTM Express instrument
(Thermo Fisher Scientific, Waltham, Massachusetts, United States). DNA samples were
stored at -20°C until analysis. The following TaqMan® allelic discrimination assays
(Applied Biosystems, Carlsbad, CA) were used for genotyping: CYP2A6*2 (rs1801272,
assay ID: C__27861808_60), CYP2A6*9 (rs28399433, assay ID: C__30634332_10),
CYP2A6*12 (rs4803380, assay ID: C__32350075_20). A TaqMan® gene copy number
assay (Applied Biosystems, Carlsbad, CA) was utilized to detect gene deletion (*4) and
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duplication (assay ID: Hs07545274_cn). Hardy-Weinberg equilibrium was assessed for
all genotypes using the chi-square goodness-of-fit test. Individuals with one copy of the
CYP2A6*9 decreased-function allele were categorized as intermediate metabolizers;
those with two copies of the CYP2A6*9 allele or one or two copies of loss-of-function
alleles (CYP2A6*2, *4, and *12) were categorized as slow metabolizers as described
previously [7].

2.2.5

Clinical data collection

Patient demographics including age, height, weight, ethnicity, and medication history
were documented at the time of the first blood draw, and the letrozole start date was
recorded. Cancer stage, as well as ER, progesterone receptor (PR), and human epidermal
growth factor 2 (HER2) status were collected from the patients’ medical chart.

2.2.6

Instruments

Patients were asked to complete two musculoskeletal questionnaires, the AUSCAN
version 3.1 and the WOMAC version 3.1, which were previously validated as sensitive
measures for AI-induced arthralgia [14]. The AUSCAN is a 15-item questionnaire
assessing pain, stiffness, and physical function in the upper body extremities, with
possible scores ranging from 0-20 for pain, 0-4 for stiffness, and 0-36 for physical
function [15]. The WOMAC is a 24-item questionnaire that assesses pain, stiffness, and
physical function in the lower extremities, with possible scores ranging from 0-20 for
pain, 0-8 for stiffness, and 0-68 for physical function [15]. For both instruments and their
subscales, higher scores represent worse symptoms. Both questionnaires were completed
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by participants at the time of each of the three blood draws: prior to letrozole therapy
initiation, at two months post-initiation, and six months post-initiation.

2.2.7

Statistical analysis

All statistical analyses were performed using R (version 3.31) [17] and GraphPad Prism
(version 6.0, San Diego, CA) statistical software. All tests were two-sided and were
considered statistically significant at P ≤ 0.05. A student’s t-test was performed to
determine whether letrozole plasma concentration differed between patients who were
normal and reduced metabolizing patients. A linear mixed effect model was used to
assess the association between letrozole plasma concentration, genotype, and time since
last dose while adjusting for BMI and age. The same linear mixed effects model was used
for modelling AUSCAN and WOMAC scores repeatedly measured over time. We
compared adjusted mean questionnaire scores at each visit to estimate the effect of time
by visit while adjusting for age, BMI, and genotype. Multiple linear regression analyses
were performed to assess the effects estimate of age, BMI, and letrozole concentration on
the outcome of change in AUSCAN and WOMAC scores. P values for these estimates
were adjusted for multiple testing using the Holm-Bonferroni method.

2.3 Results
2.3.1

Patient demographics and medication history

We analyzed clinical variables and letrozole concentration data from 126 patients with
participant characteristics summarized in Table 2.1. Of these, 116 (92.1%) completed at
least two months of treatment and returned for follow-up visit 1, and 83 (65.9%)
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completed the six-month follow-up 2 visit (Figure 2.1). The majority of patients were
Caucasian (92.4%). Patients were not on any CYP2A6 inhibiting drugs (methoxsalen,
selegiline, tranylcypromine, ketoconazole) [18]. All patients were initiated on the
standard dose of 2.5mg of letrozole, with no adjustments in the dose.
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Table 2.1 Patient demographics (n = 126)
Patient characteristic
Age (Median (Min, Max))
BMI (Median (Min, Max))
Race/Ethnicity (N (%))
Caucasian
Asian
Other
ER status (N (%))
Positive
Negative
PR status (N (%))
Positive
Negative
HER2 status (N (%))
Positive
Negative
Stage of cancer (N (%))
I (A/B)
II (A/B)
III (A/B/C)
IV

65.5 (31, 88)
29.3 (20.1, 52.6)
118 (92.4%)
2 (1.6%)
6 (4.8%)
126 (100%)
0
106 (84.1%)
20 (15.9%)
16 (12.6%)
110 (87.3%)
38 (30.2%)
68 (54.0%)
20 (15.8%)
0

BMI body mass index; ER estrogen receptor; PR progesterone receptor; HER2 human
epidermal growth factor receptor 2
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Figure 2.1 Flow chart for patient inclusion
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2.3.2

Letrozole plasma concentrations

Plasma samples from the first and second follow-up visits were available from 105 and
66 enrolled patients, respectively. We observed a 16-fold variation in letrozole
concentration level, with a median of 90.1 ng/mL and a range of 15.1 – 247.4 ng/mL.
Time since last dose in hours was calculated for each follow-up visit. All patients had
taken their daily dose of letrozole within the past 24 hours of blood draw and patients
who self-reported non-compliance with their medication (n = 2) were excluded in the
final analysis. The time since last dose was statistically significant (P = 0.01) when age,
BMI, and genotype were corrected for, however the effect estimate of time since last dose
was minimal (effect estimate = -0.84 [95%CI, -1.48 to -0.18]), meaning that for each
hour of time, letrozole concentration decreased 0.84 ng/mL. This indicates that time since
last dose has very little impact on letrozole concentration and is consistent with the
known long half-life (48 hours) of letrozole, demonstrating that patients were at a steadystate concentration.

2.3.3

Effect of genotype and clinical variables on letrozole
concentration

CYP2A6 genotype information is summarized in Table 2.2. Patients were classified as
normal (n = 92; *1/*1), intermediate (n = 23; *1/*9), or slow (n = 11; *9/*9, *1/*2,
*1/*4, *1/*12) metabolizers of letrozole based on their genotype as previously
characterized [7]. Accordingly, 34 (27.0%) of patients were determined to have CYP2A6
reduced-function genotypes. We did not detect any gene duplication of CYP2A6 in this
patient population. Normal metabolizers had significantly lower plasma letrozole
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concentrations (median, 82.53 (min, max; 15.10, 179.70) ng/mL) than reduced
metabolizers (median, 116.80 (min, max; 75.56, 247.40) ng/mL) (P < 0.0001) (Figure
2.2). Letrozole concentration was significantly associated with both BMI (effect estimate
= -1.92, [95% CI, -2.91 to -0.92], P = 0.0001) and age (effect estimate = 0.96 [95% CI,
0.04 to 1.88, P = 0.04) (Figure 2.3). When taking repeated visits into account, as well as
adjusting for age, BMI, and time since last dose, the reduced metabolizer genotype
remained significantly associated with letrozole concentration; the letrozole concentration
level for those with reduced metabolizer genotypes was 36.55 ng/mL higher on average
than that for those with normal metabolizer genotypes ([95% CI, 22.63 to 50.47], P <
0.0001).
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Table 2.2 SNP information and genotyping quality control (n = 126)

Gene
CYP2A6
CYP2A6
CYP2A6
CYP2A6

Common
allele
name
*2
*4
*9
*12

Allelic
rs ID
change
rs1801272
1799T>A
N/A
gene deletion
rs28399433
-48T>G
rs4803380 translocation

Call
rate
1.0
1.0
1.0
1.0

MAF
in this
cohort
0.03
0.004
0.09
0.008

HWE
P
value
0.01
0.89
0.96
0.92

SNP single nucleotide polymorphism; MAF minor allele frequency; HWE Hardy–
Weinberg equilibrium
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P < 0.0001
250

Letrozole (ng/ml)

200
150
100
50
0

Normal
metabolizer
(n = 80)

Reduced
metabolizer
(n = 27)

Figure 2.2 Plasma letrozole concentration significantly associated with CYP2A6
genetic variation
Statistical test: student’s t-test
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Figure 2.3 Influence of age and BMI on letrozole concentration
Letrozole concentration was positively associated with (a) age (R2 = 0.040, P = 0.043)
and inversely associated with (b) BMI (R2 = 0.1181, P = 0.0003). Solid line linear
regression line; dotted lines 95% confidence intervals. Statistical test: Linear mixed
effects model.
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2.3.4

Measurement of arthralgia symptoms

For patients who completed follow-up visit 1, 64 of 116 (55.2%) experienced increases in
their AUSCAN score, and 62 of 116 (53.4%) experienced increases in their WOMAC
score compared to baseline. For patients who completed a second follow-up visit, 44 of
the 83 (53.0%) experienced score increases on the AUSCAN, and 42 of the 83 (50.6%)
experienced score increases on the WOMAC compared to baseline. Mean AUSCAN and
WOMAC scores at each follow-up visit and the effect estimate of time by visit (adjusted
by age, BMI, and genotype) using a mixed effects regression model are summarized in
Table 2.3. We observed positive effect estimate of time on mean scores; mean scores
increased from baseline to the first and second follow-up visits for the WOMAC for each
measure (pain, stiffness, physical functioning and total score). We observed positive
effect estimate of time between mean scores from baseline to the second follow-up for
each AUSCAN measure (pain, stiffness, physical functioning and total score) and for
pain and total score for the first follow-up visit. All of the visit effects were positive for
each WOMAC and AUSCAN measure comparing visits 1 and 2 to the baseline,
indicating that pain, stiffness, and difficulty with physical function increased over the
follow-up periods. Furthermore, 42 of 126 patients (33.3%) discontinued their letrozole
due to intolerable arthralgia. The mean time to discontinuation for patients who stopped
using the medication was 140 days (SD = 108 days) with a median time to
discontinuation of 92 days. Patients who discontinued letrozole before the first or second
follow-up were excluded from the analysis and did not provide follow-up samples or
questionnaires. Specifically, eight patients discontinued letrozole due to arthralgia
between baseline and follow-up visit 1. A sub-analysis of the patients who discontinued
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between follow-up visit 1 and follow-up visit 2 due to arthralgia (n = 26) and the patients
who continued on letrozole for at least 6 months and completed their second follow-up
visit (n = 83) revealed that the group that discontinued had a significantly higher change
in AUSCAN scores at follow-up visit 1 (P = 0.027). Letrozole level, age, BMI, and
WOMAC score were not significantly different between the two groups.
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Table 2.3 Adjust mean questionnaire scores at three time points
Baseline
(n = 126)
AUSCAN
Pain
Stiffness
Physical functioning
Total score
WOMAC
Pain
Stiffness
Physical functioning
Total score

Follow-up visit 1
(n = 116)

Mean

Mean

Estimate

95% CI

Sig.

2.34
0.72
4.55
7.61

3.31
0.88
5.15
9.36

0.97
0.16
0.60
1.75

0.29 to 1.66
-0.02 to 0.34
-0.39 to 1.58
0.12 to 3.37

*
*
*
*

2.95
1.66
9.29
13.90

3.69
2.03
11.66
17.4

0.74
0.37
2.37
3.50

0.13 to 1.36
0.06 to 0.68
0.73 to 4.01
1.18 to 5.81

*
*
*
*

(Table 2.3 continued)

Mean
AUSCAN
Pain
Stiffness
Physical functioning
Total score
WOMAC
Pain
Stiffness
Physical functioning
Total score

Follow-up visit 2
(n = 82)
Estimate
95% CI

4.16

1.82

1.02 to 2.62

1.12

0.40

0.19 to 0.61

6.88

2.33

1.19 to 3.48

12.24

4.62

2.73 to 6.52

4.04

1.09

0.38 to 1.81

2.22

0.56

0.20 to 0.92

12.94

3.64

1.73 to 5.56

19.20

5.32

2.61 to 8.03

Sig.
*
*
*
*
*
*
*
*

AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and
McMaster Osteoarthritis Index; CI confidence interval Sig. Significant. Statistical test:
mixed effects regression model. All scores and effect estimates are corrected for age,
BMI, and genotype. Significance indicates that the 95% confidence interval for the effect
estimate does not cross zero.
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2.3.5

Letrozole concentration does not affect WOMAC and
AUSCAN scores

Simple linear regression analyses showed that a change in AUSCAN scores was not
significantly associated with steady-state letrozole concentration at follow-up visit 1 (n =
105) or follow-up visit 2 (n = 66). Changes in WOMAC scores at follow-up visit 1 (n =
105) and follow-up visit 2 (n = 66) suggested a very weak negative association with
letrozole concentration. However, when P values were corrected for multiple testing
using the Holm-Bonferroni method, the change in WOMAC score was not found to be
associated with letrozole concentration, age or BMI (Table 2.4)

64

Table 2.4 Influence of clinical factors on change in WOMAC and AUSCAN scores
Outcome
Change in WOMAC
(Follow-up visit 1)
Change in WOMAC
(Follow-up visit 2)
Change in AUSCAN
(Follow-up visit 1)
Change in AUSCAN
(Follow-up visit 2)

Predictor
variable
Age
BMI
[Letrozole]
Age
BMI
[Letrozole]
Age
BMI
[Letrozole]
Age
BMI
[Letrozole]

Effect
estimate
-0.132
0.077
-0.445
-0.100
0.083
-0.857
-0.079
0.024
-0.331
-0.118
-0.080
-0.883

95% CI
-0.260 to -0.003
-0.030 to 0.184
-1.041 to 0.151
-0.203 to 0.005
-0.020 to 0.187
-1.608 to -0.105
-0.258 to 0.100
-0.124 to 0.172
-1.159 to 0.498
-0.286 to 0.049
-0.229 to 0.068
-1.964 to 0.199

P value
0.045
0.156
0.141
0.062
0.115
0.026
0.383
0.744
0.43
0.162
0.283
0.108

Adjusted
P value
0.135
0.282
0.282
0.124
0.124
0.078
1.000
1.000
1.000
0.324
0.324
0.324

AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and
McMaster Osteoarthritis Index; CI confidence interval; Statistic test: Linear regression. P
value was adjusted using the Holm–Bonferroni method
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2.3.6

CYP2A6 genotype does not predict arthralgia symptoms

There was no difference in combined pain scores between reduced metabolizers relative
to those in normal metabolizers at the first follow-up visit (n = 116, P = 0.30) and second
follow-up visit (n = 83, P = 0.76) time points (Figure 2.4) using two-tailed unpaired ttests. A linear random intercept model was utilized to account for repeated measures and
adjust for age and BMI, failed to detect an association between increased WOMAC and
AUSCAN scores for follow-up visit 1 (effect estimate = -0.39 [95% CI, -5.70 to 4.92], P
= 0.886) or follow-up visit 2 (effect estimate = -0.87 [95% CI, -7.04 to 5.29], P = 0.78).
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(n = 22)
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Figure 2.4 No association was found between change in pain score and CYP2A6
genotype
No association was found between change in pain score and CYP2A6 activity the first
follow-up visit (n = 116, R2 = 0.009, P = 0.2981) or second follow-up visit (n = 83, R2 =
0.001, P = 0.7530). Statistical test: linear random intercept model was utilized to account
for repeated measures and adjust for age and BMI
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2.4 Discussion
This is the first study to use the AUSCAN and WOMAC assessment tools to measure the
effect of letrozole concentration and CYP2A6 genotype on letrozole-induced arthralgia in
patients with ER-positive breast cancer. In this prospective cohort of 126 patients, we
confirmed that there was a significant association between letrozole concentration and
CYP2A6 genotype. However, changes in AUSCAN and WOMAC scores were not
associated with letrozole concentration. Furthermore, the CYP2A6 genotype was not
significantly associated with a change in arthralgia symptoms. Thus, these results suggest
that systemic letrozole concentrations and CYP2A6 genotype are not clinically
meaningful predictors of AI-induced arthralgia.
Thirty-four patients (27%) in this study had a genotype that is associated with
decreased CYP2A6 function. Patients carrying at least one of the CYP2A6 reducedfunction genotypes (*2, *4, *9, or *12) had significantly higher steady-state letrozole
concentrations than patients lacking these variations. This finding is consistent with
previous studies [7, 13]. We observed a 16-fold variation in the plasma concentration of
letrozole level, which was significantly associated with CYP2A6 genotype, age, and BMI.
The CYP2A6 genotype accounted for 17% of the explained variability, while BMI and
age accounted for 12% and 4%, respectively.
The AUSCAN and WOMAC are validated self-report tools that effectively assess
pain, stiffness and physical function changes, and can detect early letrozole-induced
arthralgia symptoms. In this cohort, we found that mean scores on each subscale of the
AUSCAN and WOMAC increased over the duration of letrozole treatment, indicating
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worsening pain, stiffness, and physical function. Of note, the most substantial increase in
AUSCAN and WOMAC scores occurred between baseline and follow-up visit 1,
indicating arthralgia symptoms do not appear to increase linearly over time. Patients with
an increase in AUSCAN score at follow-up visit 1 were more likely to be in the group
that discontinued their medication by follow-up visit 2. However, individual factors such
as stage of cancer and risk of recurrence may influence patient motivation for continuing
on therapy despite AI-induced arthralgia. Further research is needed to determine whether
clinicians could utilize these tools to predict which patients may discontinue letrozole
therapy due to intolerable arthralgia. Clinicians may be able to better measure arthralgia
symptoms by asking patients to complete AUSCAN and WOMAC questionnaires at
regular intervals throughout the course of letrozole therapy, either through paper
questionnaires or by recording the data in an electronic mobile phone application. These
measures have been adapted and validated for mobile phone use to electronically capture
the pain, stiffness, and physical function data, as well as recording date and time of
assessment [19, 20]. Data can then be sent electronically to their physician where it can
be stored in their electronic health record and evaluated, better informing clinicians of
their patients’ response to medication and potential for discontinuation.
An advantage of our study is that we collected data prospectively, and blood samples
were taken at the same time as the AUSCAN and WOMAC were administered. The
AUSCAN and WOMAC request that patients comment on the severity of their most
recent symptoms from the past 48 hours [15]. Because letrozole has a long half-life [5]
and time since last dose was recorded, letrozole levels in compliant patients were
assumed to be in steady state. Our measurements of symptoms and drug levels were
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robust, and therefore method inaccuracy is unlikely to explain an absence of an observed
association. A larger study may confirm our findings with a greater degree of certainty.
A limitation of this study was the difficulty in collecting plasma samples or
questionnaires from patients who discontinued their drug between the baseline and
follow-up visits. Thus, for those patients, it is difficult to determine whether arthralgia
was associated with letrozole plasma concentration. We were not able to analyze data
from patients who discontinued letrozole before follow-up visit 1 as letrozole
concentration, and AUSCAN and WOMAC scores were not collected. However, we did
perform a sub-group analysis on the patients who discontinued their letrozole between
follow-up visit 1 and follow-up visit 2. We found that those who discontinued had a
significantly higher mean change in AUSCAN scores at follow-up visit 1 compared to
patients who remained on letrozole therapy for the full 6 months. This provides further
evidence that AUSCAN and WOMAC scores should be investigated as potentially
predictive clinical assessment tools.
There are likely other clinical characteristics and genetic factors contributing to
changes in pain, stiffness, and physical function scores, and the probability of patients
discontinuing letrozole treatment due to arthralgia. A prospective study of 135 female
patients with no prior pain who were on aromatase inhibitors investigated a number of
different clinical, biological, environmental, and genetic risk factors for the development
of arthralgia [21]. The authors found that patient anxiety may be a predictor of the
development of AI-induced arthralgia [21]. As we did not measure anxiety, depression,
or other psychological factors, further investigation is needed to replicate these findings.
Additional SNPs in estrogen and inflammation pathways have been found to be
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associated with AI-induced arthralgia in candidate gene and genome-wide analyses [4,
22]. However, these genetic findings remain to be replicated in prospective studies in
order to determine if they are reliable predictors of AI-induced arthralgia.
Overall, this study indicates that CYP2A6 genotype, age, and BMI are predictors of
letrozole concentration. Although we did not observe an association between letrozole
levels and arthralgia symptoms, we did find that the AUSCAN and WOMAC instruments
are very useful measures of AI-induced pain, stiffness, and changes in physical function.
These measures may be applied in clinical practice to monitor AI adverse effects. They
could also be used to further investigate AI-induced arthralgia mechanisms as well as
therapeutic interventions to reduce arthralgia.
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3

GENETIC AND CLINICAL PREDICTORS OF
AROMATASE INHIBITOR ARTHRALGIA IN BREAST
CANCER PATIENTS
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3.1 Introduction
Breast cancer is the most common cancer in females worldwide, as well as the leading
cause of cancer death in women [1]. As many as 80% of breast cancers are estrogen
receptor (ER)-positive, meaning that the tumour grows in response to estrogen [2]. Antiestrogen therapy includes tamoxifen for pre-menopausal women and aggressive tumours.
Aromatase inhibitors (AIs) are well established as the most effective first-line endocrine
treatment for postmenopausal women with ER-positive breast cancer and the most
commonly used treatment in North America [3]. Aromatase inhibitors work through their
inhibition of the aromatase enzyme, which is encoded by the CYP19A1 gene [4].
Aromatase catalyzes the final step in the estrogen production pathway [5]. By inhibiting
aromatase, these drugs reduce the amount of estrogen to nearly undetectable levels. All
three aromatase inhibitors, letrozole, anastrozole, and exemestane have nearly identical
effectiveness in reducing estrogen levels, but also have similar adverse drug reaction
(ADR) profiles. The clinical impact of AIs varies widely among patients and up to 50%
of patients experience ADRs, with the most common being arthralgia. These reactions
adversely impact the quality of life for patients, leading to compromised compliance and
contribute to early discontinuation [6]. The mechanism of the ADRs is largely unknown.
A number of different scales and measures have been employed to evaluate the
intensity of the pain and stiffness that a patient with AI-induced arthralgia experiences, as
well as the effect on the patient’s quality of life. A prospective, longitudinal study by
Swenson et al. [7] examined the responsiveness of standardized self-reported measures of
AI-induced arthralgia, comparing six different questionnaires administered to 122
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patients assessed at baseline, and at one, three, and six months post-initiation of therapy.
They concluded that the Australian/Canadian Osteoarthritis Hand Index (AUSCAN), the
Western Ontario and McMaster Osteoarthritis Index (WOMAC) had the greatest
sensitivity and responsiveness in detecting and measuring AI-induced arthralgia.
Previous pharmacogenomic studies have attempted to identify biomarkers that predict
drug response by investigating the association of ADRs with genetic variation in patients.
Polymorphisms within genes in the estrogen pathway (CYP19A1, ESR1) and genes
associated with inflammation (OPG, TCLA1, RANKL) have been shown to be associated
with AI arthralgia [8]. Although several candidate SNPs have been identified, there are
no established clinical practice guidelines currently, so a personalized medicine approach
cannot be implemented within a clinical setting. Replication and validation of these
biomarkers are an essential next step to advance these discoveries into implementation in
patient care. We conducted a prospective study of patients treated with AIs and measured
their arthralgia through the course of their treatment using the validated AUSCAN and
WOMAC questionnaires.

3.2 Methods
3.2.1

Study design and participants

Female patients (n = 196) who were prescribed AI therapy were recruited from the
London Regional Cancer Program, London, Ontario, Canada between April 2015 and
December 2017. All study participants provided written informed consent. The study was
approved by the Research Ethics Board at the University of Western Ontario.
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3.2.2

Demographics and medication history

Demographic information including gender, age, height, weight, and ethnicity of the
participants was recorded at the patient’s initial clinic visit. The type of AI prescribed,
dose, date of initiation, and concomitant medication history were also recorded. At each
follow-up visit, participants were asked whether they were still on AI treatment, and if
not, the reason they had stopped and the date of their last dose. The cancer stage, as well
as ER, progesterone receptor (PR), and human epidermal growth factor receptor 2
(HER2) status were collected from the patients’ medical chart.

3.2.3

Sample collection and storage

Blood samples were obtained from each patient at three time points: prior to AI therapy
initiation, approximately two months’ post-initiation, and six months’ post-initiation on
2.5mg of letrozole or 1mg of anastrozole. Blood samples were immediately stored at 4°C
before DNA extraction.

3.2.4

Arthralgia assessment

Participants were assessed at three time points: A baseline assessment was completed
prior to initiation on AI therapy, at approximately two months post initiation and again at
six months post initiation. The AUSCAN, version 3.1 and the WOMAC, version 3.1
questionnaires were administered during clinic visits where blood samples were obtained.
The AUSCAN is a 15-item questionnaire that assesses pain, stiffness, and physical
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functioning of the hands. The WOMAC is a 24-item questionnaire that evaluates pain,
stiffness, and physical functioning in the lower extremities, knees, and hips.

3.2.5

Genotyping

Patient DNA was extracted from whole blood in EDTA tubes using either the MagNA
Pure Compact instrument (Roche, Laval, Quebec, Canada) or the MagMaxTM Express
instrument (Thermo Fisher Scientific, Waltham, Massachusetts, United States). DNA
samples were stored at -20°C until analysis. TaqMan® allelic discrimination assays
(Applied Biosystems, Carlsbad, CA) were performed for the following SNPs: CYP19A1
(rs4775936,

assay

ID:

C__11301451_10);

ESR1

(rs9322336,

assay

ID:

C__29568677_10; rs2234693, assay ID: C___3163590_10; and rs9340799, assay ID:
C___3163591_10); OPG (rs2073618, assay ID: C___1971047_1_); RANKL (rs7984870,
assay ID: C__29811035_20); and TCL1A (rs11849538, assay ID: C___1927667_10).
The Hardy-Weinberg equilibrium was assessed for all genotypes using Chi-square
goodness-of-fit test.

3.2.6

Statistical analyses

All statistical analyses were performed using R (version 3.31)[9] and GraphPad Prism
(version 6.0, San Diego, CA) statistical software. All tests were two-sided and were
considered statistically significant at P ≤ 0.05. Logistical regression was performed on
each SNP using the development of arthralgia and discontinuation of drug as the outcome
measure, correcting for the clinical variables of age and BMI. The time from initiation to
discontinuation of AI therapy was compared among the three genotype groups of

78

CYP19A1 using the log-rank test. For patients who did not discontinue treatment, the date
of the last follow-up inquiry confirming that they were on AI treatment was recorded.
Cox regression analysis was used to test for an independent contribution of the treatment
variable. We report the odds ratio (OR) and the corresponding P value for each covariate.
The odds ratio can be interpreted as the relative risk for development of AI arthralgia and
discontinuation of AI therapy.

3.3 Results
3.3.1

Patient demographics

The patient (n = 196) characteristics are summarized in Table 3.1. Our study population
was primarily of Caucasian ethnicity (93.9%, self reported). The median age was 65, and
all but one patient were 50 years of age or older, and had proceeded through menopause.
One 31-year-old patient had become menopausal surgically with a total abdominal
hysterectomy with bilateral salpingo-oophorectomy. All patients were initiated on either
the standard dose of 2.5mg of letrozole or 1mg of anastrozole with no adjustments in the
dose. Although exemestane was also available as a therapeutic option, none of the
patients enrolled in our study were initiated on exemestane. Of the 196 patients, 186
patients (94.9%) completed at least two months of treatment and returned for a follow-up
visit and 138 patients (70.4%) completed at least six months of AI therapy and returned
to the clinic for a second follow-up visit.
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3.3.2

AI-induced arthralgia and early discontinuation of AI
treatment

We measured arthralgia in our population using the AUSCAN and WOMAC
questionnaires. Of the 196 patients, 104 (53.1%) reported joint pain or stiffness after
initiation on an AI. The mean scores on all measures of both the AUSCAN and WOMAC
increased significantly at each follow-up visit (Table 3.2). Of note, there was a positive
association between BMI and both AUSCAN (P = 0.001, estimate = 0.370 [95% CI,
0.160 to 0.581]) and WOMAC (P < 0.0001 estimate = 0.872 [95% CI, 0.561 to 1.183])
scores at baseline before AI initiation, adjusting for age. However, baseline AUSCAN (P
= 0.123) and WOMAC (P = 0.490) scores did not predict the development of AI-induced
arthralgia, after adjusting for age and BMI. Fifty-five patients (28.1%) discontinued AI
therapy due to intolerable arthralgia, with a median time to discontinuation of 92 days.
The mean time to discontinuation was 148 days (SE = 16.68). Two additional patients
discontinued AI therapy for reasons other than arthralgia, including hair loss and mood
changes.
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Table 3.1 Patient characteristics

Age (Median (Min, Max))
BMI (Median (Min, Max))

Letrozole
(n = 125)
65 (31, 88)
30.1 (20.1,
52.6)

Anastrozole
(n = 71)
65 (50, 84)
28.9 (18.6,
45.3)

Total
(n = 196)
65 (31, 88)
29.2 (18.6,
52.6)

Race/Ethnicity (N (%))
Caucasian
117 (93.6%)
67 (94.3%)
184 (93.9%)
Asian
2 (1.6%)
1 (1.4%)
3 (1.5%)
Other
6 (4.8%)
3 (4.3%)
9 (4.6%)
ER status (N (%))
Positive
125 (100%)
71 (100%)
196 (100%)
Negative
0
0
0
PR status (N (%))
Positive
105 (84.0%)
60 (84.5%)
165 (84.2%)
Negative
20 (16.0%)
11 (15.5%)
31 (15.8%)
HER2 status (N (%))
Positive
16 (12.8%)
10 (14.1%)
26 (13.3%)
Negative
109 (87.2%)
61 (85.9%)
170 (86.7%)
Stage of cancer (N (%))
I (A/B)
38 (30.4%)
34 (47.9%)
72 (36.7%)
II (A/B)
67 (53.6%)
33 (46.5%)
100 (51.0%)
III (A/B/C)
20 (16.0%)
4 (5.6%)
24 (12.2%)
IV
0
0
0
Prior chemotherapy (N (%))
Yes
65 (52.0%)
25 (35.2%)
90 (45.9%)
No
60 (48%)
46 (64.8%)
106 (54.1%)
Prior taxane use (N (%))
Yes
60 (48.0%)
21 (29.6%)
81 (41.3%)
No
65 (52.0%)
50 (70.4%)
115 (58.7%)
BMI body mass index; ER estrogen receptor; PR progesterone receptor; HER2 human
epidermal growth factor receptor 2
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Table 3.2 Mean questionnaire scores at the three study time points
Baseline
(n = 196)
AUSCAN
Pain
Stiffness
Physical functioning
Total score
WOMAC
Pain
Stiffness
Physical functioning
Total score

Follow-up visit 1
(n = 186)

Mean

Mean

Estimate

95% CI

Sig.

2.46
0.76
4.39
7.61

3.2
0.91
5.01
9.12

0.83
0.16
0.77
1.77

0.32 to 1.33
0.02 to 0.29
0.01 to 1.52
0.55 to 2.98

*
*
*
*

2.92
1.59
8.90
13.41

3.58
2.03
11.13
16.74

0.74
0.44
2.46
3.65

0.26 to 1.22
0.20 to 0.68
1.14 to3.77
1.81 to 5.49

*
*
*
*

(Table 3.2 continued)

Mean

Follow-up visit 2
(n = 138)
Estimate
95% CI

Sig.

AUSCAN
Pain
3.63
1.44
0.87 to 2.00
*
Stiffness
1.10
0.37
0.23 to 0.52
*
Physical functioning
6.17
2.22
1.37 to 3.06
*
Total score
10.90
4.08
2.71 to 5.44
*
WOMAC
Pain
3.95
1.20
0.66 to 1.73
*
Stiffness
2.10
0.54
0.28 to 0.81
*
Physical functioning 12.21
4.04
2.56 to 5.52
*
Total score
18.15
5.80
3.73 to 7.85
*
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and
McMaster Osteoarthritis Index; CI confidence interval; Sig. Significant. Statistical test:
linear regression model. All effect estimates are corrected for age, BMI, and genotype.
Significance indicates that the 95% confidence interval for the effect estimate does not
cross zero.
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Table 3.3 Association of arthralgia with clinical variables
Univariate analysis
Unadjusted Odds
P value
Ratio
95% CI
Intercept
Age (years)
BMI (kg/m2)
Aromatase inhibitor

0.584
0.001
Letrozole
reference
Anastrozole
0.023
Prior chemotherapy
Yes
reference
No
0.519
Prior taxane therapy Yes
reference
No
0.557
Luminal status
Luminal A
reference
Luminal B
0.241
Cancer stage
reference
I (A/B)
0.773
II (A/B)
0.556
III (A/B/C)
CI confidence interval; BMI body mass index

0.990
1.088

0.956 to 1.026
1.035 to 1.144

0.504

0.279 to 0.910

0.831

0.473 to 1.460

0.843

0.476 to 1.491

0.607

0.264 to 1.399

1.094
0.757

0.596 to 2.008
0.300 to 1.913

(Table 3.3 continued)

Intercept
Age (years)
BMI (kg/m2)
Aromatase inhibitor

Multivariable analysis
Adjusted Odds
P value
Ratio
95% CI
0.374
0.255
0.757
0.993
0.952 to 1.036
0.001
1.088
1.037 to 1.152

Letrozole
Anastrozole
0.018
Prior chemotherapy
Yes
reference
No
0.720
Prior taxane therapy Yes
reference
No
0.970
Luminal status
Luminal A reference
Luminal B
0.285
Cancer stage
reference
I (A/B)
0.453
II (A/B)
0.276
III (A/B/C)
CI confidence interval; BMI body mass index

0.462

0.244 to 0.877

0.765

0.178 to 3.294

0.971

0.208 to 4.523

0.611

0.248 to 1.508

0.761
0.534

0.372 to 1.555
0.173 to 1.651

Statistical tests: Logistical and linear regression models.
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3.3.3

Clinical variables associated with AI arthralgia

BMI was significantly associated with AI-induced arthralgia (P = 0.001; OR = 1.088 [CI
95%, 1.025 to 1.144], Table 3.3) and this significance was maintained in the
multivariable analysis. The odds ratio for this clinical variable was quite small, indicating
that although this is a precise predictor of arthralgia, it only influences its development to
a small degree. BMI was not found to be a predictor for discontinuation of therapy (P =
0.113; OR = 1.039 [CI 95%, 0.991 to 1.090]). The development of arthralgia symptoms
was significantly less in patients prescribed anastrozole compared to letrozole in both the
univariate (P = 0.023; OR = 0.504 [95% CI, 0.279 to 0.910], Table 3.3) and multivariable
analyses (P = 0.018; OR = 0.462 [95% CI, 0.244 to 0.877], Table 3.3). Patients
prescribed anastrozole were significantly less likely to discontinue their drug due to AIinduced arthralgia than patients prescribed letrozole (P = 0.032; OR = 0.464 [CI 95%,
0.230 to 0.934]) after adjusting for age and BMI. The odds ratio indicates that patients on
letrozole were more than twice as likely to discontinue their AI.

3.3.4

Pharmacogenetic variables associated with AI arthralgia

SNP genotyping information is summarized in Table 3.4. Four SNPs, one in CYP19A1
(rs4775936) and three in ESR1 (rs9322336, rs2234693, rs930799) were significantly
associated with the development of arthralgia when controlling for the clinical variables
of age and BMI (Table 3.5). Interestingly, the SNP in CYP19A1 (rs4775936) was
significantly associated with discontinuation of drug due to arthralgia when controlling
for age and BMI (Table 3.6). Using a Cox regression analysis, CYP19A1 (rs4775936)
was also significantly associated with discontinuation of drug due to arthralgia (log
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ranked P = 0.035, Figure 3.1). The SNPs in selected genes associated with inflammation
(OPG, TCLA1, RANKL) were not associated with either arthralgia or early
discontinuation of drug due to arthralgia. Because the results of previous studies on
RANKL suggested that there might be a recessive effect of the G allele, we repeated the
genetic association for this SNP using a recessive genetic model, adjusting for age and
BMI, but did not find that it was associated with AI-induced arthralgia (P = 0.233; OR =
1.464 [95% CI, 0.782 to 2.738]) or discontinuation of drug (P = 0.170; OR = 1.581 [95%
CI, 0.822 to 3.041]).
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Table 3.4 SNP information and genotyping quality control

Gene
CYP19A1
ESR1
ESR1
ESR1
OPG
TCL1A
RANKL

rs ID
rs4775936
rs2234693
rs9322336
rs9340799
rs2073618
rs11849538
rs7984870

SNP location
or AA
change
Intronic
Intronic
Intronic
Intronic
Asn3Lys
Downstream
Intronic

Call rate
1.0
1.0
1.0
1.0
1.0
1.0
1.0

MAF
in this
cohort
0.44
0.42
0.24
0.30
0.49
0.12
0.43

HWE
P value
0.338
0.936
0.117
0.300
0.569
0.140
0.560

SNP single nucleotide polymorphism; MAF minor allele frequency; HWE Hardy–
Weinberg equilibrium
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Table 3.5 Genetic associations with AI arthralgia
Odds
Gene
SNP
Ratio
95% CI
P Value Sig.
CYP19A1
rs4775936
1.719
1.115 to 2.692
0.016
*
ESR1
rs9322336
0.553
0.336 to 0.896
0.018
*
ESR1
rs2234693
1.706
1.109 to 2.673
0.017
*
ESR1
rs9340799
1.626
1.014 to 2.656
0.047
*
OPG
rs2073618
1.107
0.741 to 1.660
0.619
TCL1A
rs11849538
1.146
0.637 to 2.089
0.649
RANKL
rs7984870
0.874
0.574 to 1.324
0.525
SNP single nucleotide polymorphism; Sig. significance. All associations are corrected for
age and BMI. Statistical test: logistical regression model.
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Table 3.6 Genetic associations with early discontinuation of AI
Odds
Confidence
Gene
rs ID
Ratio
Interval
P Value Sig.
CYP19A1
rs4775936
1.618
1.019 to 2.607
0.044
*
ESR1
rs9322336
0.633
0.364 to 1.061
0.092
ESR1
rs2234693
1.386
0.889 to 2.174
0.151
ESR1
rs9340799
1.515
0.924 to 2.498
0.100
OPG
rs2073618
0.976
0.630 to 1.509
0.912
TCL1A
rs11849538
1.440
0.781 to 2.607
0.231
RANKL
rs7984870
0.762
0.480 to 1.194
0.240
SNP single nucleotide polymorphism; Sig. significance. All associations are corrected for
age and BMI. Statistical test: logistical regression model.
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100

OR = 1.6 [CI 95% 1.1 to 2.6]
Log-rank P value = 0.035

Remaining on AI
(Proportion)

75
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C/C
C/T
T/T
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15

18

21

24

Time (months)
Figure 3.1 Time to treatment discontinuation for patient-reported AI arthralgia
CYP19A1 (rs4775936) genotype (C/C, C/T, and T/T). The proportion of patients
remaining on the first aromatase inhibitor medication is given on the y-axis. AI,
aromatase inhibitor; OR, odds ratio. Statistical test: Cox regression model.
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3.4 Discussion
In this prospective analysis of arthralgia in early stage breast cancer patients treated with
AIs, we observed that more than half of patients developed arthralgia symptoms during
treatment with AIs. We found that nearly one-third of patients discontinued AI therapy
due to severe and intolerable musculoskeletal adverse reactions. Our results are consistent
with previous studies in which compliance to AI therapy was compromised by ADRs,
primarily musculoskeletal in nature [6, 10].
The etiology of AI-induced arthralgia is relatively unclear, although different
mechanisms and pathways have been identified [8]. Our study focused on mechanismspecific predictors of AI-induced arthralgia in the estrogen and inflammation pathways.
CYP19A1 is a gene that encodes aromatase, an enzyme responsible for the biosynthesis of
estrogen and the protein target of AIs. A study by Garcia-Giralt et al. (2013) found that
the CYP19A1 SNP rs4775936 was associated with worsened arthralgia pain [11]. In our
study, we found that rs4775936 was not only associated with arthralgia but also predicted
early discontinuation of AI therapy due to arthralgia. SNPs in ESR1 (rs9322336,
rs2234693, rs930799) also have been found to be associated with the development of AIrelated musculoskeletal symptoms [12, 13]. ESR1 is a gene which encodes estrogen
receptor alpha (ER-α), which is an estrogen-activated transcription factor. ER-α is the
primary receptor in the estrogen signalling pathway, and its expression is the defining
feature of ER-positive breast cancer [14]. The intronic variant in ESR1 (rs9322336) was
found to be associated with AI-induced arthralgia in patients treated with exemestane
[12]. Although our population was treated with letrozole and anastrozole only, we found
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that rs9322336 was associated with the development of arthralgia, indicating that this
SNP might predict arthralgia for all three AIs.
We were unable to validate previously reported findings that demonstrated that a SNP
(rs11849538) near the TCL1A gene was associated with a decrease in arthralgia. This
SNP was identified in a genome-wide association study of breast cancer patients in the
MA.27 phase III clinical trial. Previous pharmacogenetic studies of RANKL (rs7984870)
demonstrated that the G allele was protective of AI-induced arthralgia [15], and patients
homozygous for the G allele of rs7984870 in RANKL had a lower risk of musculoskeletal
ADR-associated treatment discontinuation [16]. The rs7984870 SNP was not
significantly associated with arthralgia or discontinuation of therapy in our population
when using either an additive genetic model or a recessive genetic model. OPG
(rs2073618) is a missense Asn3Lys SNP that was originally found to be associated with
decreased OPG expression and an increased risk of musculoskeletal ADRs in a
population of breast cancer patients treated with AIs in a Chinese Han population [15]. A
recent study was unable to replicate this association between rs2073618 and the
development of musculoskeletal symptoms [16], which is consistent with our findings
that there is no association between OPG (rs2073618) and the development of AIinduced arthralgia.
It was interesting to note that the clinical variable of BMI was significantly associated
with the development of arthralgia, although the odds ratio was small, indicating that the
impact of the variable is of lower importance. BMI has been previously linked to
increased estrogen levels, as aromatase catalyzes biosynthesis of estrogen in the adipose
tissues of post-menopausal women [5].
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We observed a significant difference in tolerability between letrozole and anastrozole in
our population. However, a large meta-analysis of clinical trial data detected no
difference in musculoskeletal ADRs among patients treated with any of the three AIs
[17]. However, a prospective study evaluating musculoskeletal symptoms in early-stage
breast cancer patients treated with exemestane or letrozole found that time to treatment
discontinuation was significantly shorter in patients prescribed exemestane [10]. It is
possible that if the effect size between drugs were relatively small, it might not be
detected in a meta-analysis and would require a study with more sensitive assessment
tools of musculoskeletal symptoms. This finding requires further replication in order to
determine whether it has clinical importance.
A previous study reported that patients who had been previously treated with taxane were
more likely to report arthralgia symptoms [6]. However, two subsequent studies failed to
replicate this finding [18, 19]. We also observed that prior treatment with taxane did not
predict the development of AI-induced arthralgia.
In summary, more than half of our patients experienced treatment-emergent arthralgia
symptoms, and almost one-third of our patients discontinued their AI treatment due to
arthralgia. Both clinical and genetic factors help to explain the variation in tolerability of
AIs. We replicated previously established associations of SNPs in genes within the
estrogen-signalling pathway. Additional functional validation studies could aid in
understanding the mechanism behind these genetic associations and lead to more accurate
predictors of toxicity. Overall, our findings help to refine interventions to prevent AIinduced arthralgia and improve compliance with AI therapy.
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4

PROSPECTIVE ANALYSIS OF VITAMIN D LEVELS,
VITAMIN D RECEPTOR POLYMORPHISMS, AND
ARTHRALGIA IN POSTMENOPAUSAL WOMEN ON
AROMATASE INHIBITORS
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4.1 Introduction
Arthralgia pain, characterized by bilateral aches and pains affecting the shoulder, elbow,
hand, hip and knee joints, is a frequent adverse drug reaction (ADR) among women
prescribed AIs for treatment of estrogen receptor (ER) positive breast cancer [1-3]. The
cause of AI arthralgia is unknown, however experts in the field theorize there may be
multiple contributing factors, including vitamin D levels and SNPs in genes involved in
the vitamin D metabolic pathway [4].
Vitamin D is a hormone that can be synthesized in the skin in the presence of ultravioletB light or consumed orally through supplementation of natural and fortified food [5].
Serum 25-hydroxyvitamin D [25(OH)D] provides the most accurate assessment of
vitamin D status and is used as a biomarker in studies which measure vitamin D [6].
Vitamin D metabolism is illustrated in Figure 4.1.
Like other hormones, vitamin D plays a role in a wide range of processes in the body,
including musculoskeletal health. Vitamin D deficiency is common in populations north
of latitude 40 degrees north, in healthy postmenopausal women [7], and in women
receiving adjuvant chemotherapy for breast cancer [8]. Low vitamin D intake and low
25(OH)D have been linked to higher prevalence of musculoskeletal symptoms, including
arthralgia, in populations without breast cancer [9]. Vitamin D has been shown to play a
role in the development of AI-induced arthralgia. Some studies have found that patients
with low levels of vitamin D were more likely to develop arthralgia post-initiation on AI
therapy. One study observed that patients on AIs with musculoskeletal symptoms were
more likely to be vitamin D deficient at the time of AI initiation when compared to
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Figure 4.1 Schematic diagram of steroid and vitamin D signalling pathway
Sterol 27-hydroxylase (encoded by CYP27A1) and vitamin D 25-hydroxylase (encoded
by CYP2R1) both convert vitamin D2 and D3 to 25-hydroxyvitamin D (calcidiol). 1-αhydroxylase (encoded by CYP27B1) catalyzes the hydroxylation of 25(OH)D (calcidiol)
to the bioactive form 1,25(OH)2D (calcitriol). Calcitriol binds to the vitamin D receptor
(encoded by VDR)
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asymptomatic patients [10]. Servitja et al. found that vitamin D levels were closely
related to the intensity of the arthralgia, with the most severely affected patients having
the lowest vitamin D levels [11]. Body mass index (BMI) is a clinical factor which has
been previously shown to be inversely associated with serum 25(OH)D levels [12, 13].
Low serum 25(OH)D levels are relatively common in adults over the age of 65 [14].
More research is needed to elucidate how these different factors interact to create painful
joints in patients on AIs.
SNPs in genes in the vitamin D pathway have been previously investigated in genetic
association studies in patients on AIs. Garcia-Giralt et al. demonstrated that variants in
VDR, and CYP27B1 genes predict the risk of AI arthralgia [15]. While vitamin D levels
are known to impact the development of arthralgia, it is unclear how vitamin D levels,
genetic variation, and arthralgia interact.
In our prospective study of women initiated on AI therapy, we investigated the effect of
genetic variants in the vitamin D pathway, their effect on 25(OH)D levels, and whether
either of these two factors contributed to the development of AI arthralgia in patients with
ER-positive breast cancer.

4.2 Materials and Methods
4.2.1

Study population

196 postmenopausal breast cancer patients diagnosed with stage I-III ER-positive breast
cancer who were considering AI therapy were enrolled at the London Regional Cancer
Program in London Ontario from April 2015 – December 2017. All study participants
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provided written informed consent. The Research Ethics Board at the University of
Western Ontario approved the study.

4.2.2

Sample collection and storage

Blood samples were obtained from each patient at three time points: prior to AI therapy
initiation, approximately 2 months post-initiation, and 6 months post-initiation on 2.5mg
of letrozole or 1mg of anastrozole. Date and time of blood collection and last AI dose
were recorded and used to calculate the time (in hours) since the last dose. Blood samples
were immediately stored at 4°C before centrifugation at 2000G for 10 minutes for plasma
isolation. Plasma samples were stored at -80°C until analysis.

4.2.3

Plasma vitamin D measurement

Plasma 25-hydroxy-Vitamin D (D2 and D3) levels were measured by ELISA as per
manufacture’s protocol (BioVendor, Candler, NC). Dates of blood draw for each patient
were categorized into seasons: Winter (October-March) when the sunlight levels are
lower and summer (April to September) when sunlight levels are higher.

4.2.4

Clinical data collection

Patient demographics including age, height, weight, ethnicity, and medication history
were documented at the time of the first blood draw, and the letrozole start date was
recorded. Cancer stage, as well as estrogen receptor (ER), progesterone receptor (PR),
and HER2 status were collected from the patients’ chart.
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4.2.5

Instruments

Patients were asked to complete two musculoskeletal questionnaires – AUSCAN version
3.1 and the WOMAC version 3.1, which were previously validated as sensitive measures
for AI-induced arthralgia[16]. The AUSCAN is a 15-item questionnaire assessing pain,
stiffness, and physical function in the upper body extremities, with possible scores
ranging from 0-20 for pain, 0-4 for stiffness, and 0-36 for physical function [17]. The
WOMAC is a 24-item questionnaire that assesses pain, stiffness, and physical function in
the lower extremities, with possible scores ranging from 0-20 for pain, 0-8 for stiffness,
and 0-68 for physical function [17]. For both instruments and their subscales, higher
scores represent worse symptoms. The two questionnaires were administered to each
patient on three separate occasions and completed at the time of each of the three blood
draws: prior to AI therapy initiation, approximately 2 months post-initiation, and 6
months post-initiation.

4.2.6

Genotyping

DNA was extracted from whole blood using either a standard DNA extraction protocol
(QIAmp DNA Mini Kit, Qiagen, Valencia, California) or the MagNA Pure Compact
instrument (Roche, Laval, Quebec, Canada) and DNA samples were stored at -20°C until
analysis. VDR (rs11568820, assay ID: C___2880808_10) and CYP27B1 (rs4646536,
assay ID: C__25623453_10) Taqman allelic discrimination assays (Applied Biosystems,
Carlsbad, CA) were used for genotyping. Hardy-Weinberg equilibrium was assessed for
all genotypes using the chi-square goodness-of-fit test.
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4.2.7

Statistical analysis

All statistical analyses were performed using R (version 3.31)[18] and GraphPad Prism
(version 6.0, San Diego, CA) statistical software. All tests were two-sided and were
considered statistically significant at P ≤ 0.05.

4.3 Results
4.3.1

Patient demographics and medication history

196 postmenopausal women with breast cancer were enrolled into our study prior to
initiation on AI therapy with patient demographics and medication history summarized in
Table 4.1. Women were predominantly Caucasian (93.6%). The median age was 66 years
and the mean age was 65 years (SD = 8.1; range = 31 - 88). All patients were initiated on
the standard dose of 2.5mg of letrozole (n = 125) or 1mg of anastrozole (n = 71), with no
adjustments in the dose. In our study, 186 patients (94.9%) completed at least 2 months
of treatment returned for a follow-up 1 visit and 138 patients (70.4%) completed at least 6
months of AI therapy and returned to the clinic for a follow-up 2 visit.
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Table 4.1 Patient characteristics
Total
(n = 196)
65 (31, 88)
29.2 (18.6, 52.6)

Age (Median (Min, Max))
BMI (Median (Min, Max))
Race/Ethnicity (N (%))
Caucasian
184 (93.9%)
Asian
3 (1.5%)
Other
9 (4.6%)
ER status (N (%))
Positive
196 (100%)
Negative
0
PR status (N (%))
Positive
165 (84.2%)
Negative
31 (15.8%)
HER2 status (N (%))
Positive
26 (13.3%)
Negative
170 (86.7%)
Stage of cancer (N (%))
I (A/B)
72 (36.7%)
II (A/B)
100 (51.0%)
III (A/B/C)
24 (12.2%)
IV
0
BMI body mass index; ER estrogen receptor; PR progesterone receptor; HER2 human
epidermal growth factor receptor 2
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4.3.2

Vitamin D analysis

At the baseline visit, the median 25(OH)D level was 29.43ng/ml (10.11 – 84.26 ng/ml,
25.23 – 210.31nmol/l). One hundred women (51.0%) had vitamin D deficiency (<30
ng/ml, 75nmol/l); an additional 85 (43.3%) had vitamin D insufficiency (30 – 49 ng/ml;
75 – 125nmol/l). Only 5.6% of the women had levels that met sufficiency criteria (>50
ng/ml, >125nmol/l). Vitamin D levels are summarized in table 4.2. We did not observe a
significant effect of season (summer versus winter) on baseline 25(OH)D level (P =
0.617, (Figure 4.2). BMI was significantly associated with vitamin D levels (P < 0.0001,
estimate = -0.528, Figure 4.3). Interestingly, we found a significant association between
the development of arthralgia and vitamin D sufficiency. Patients with a 25(OH)D level
of at least 50ng/ml (>125nmol/l) were four times less likely to develop AI arthralgia,
adjusted for age, BMI, and genotype (P = 0.048, estimate = 0.263 [95% CI, 0.070 to
0.988]).

4.3.3

Pharmacogenetic analysis

Genotyping information is summarized in Table 4.3. We found that there was a
significant association between CYP27B1 (rs4646536) and an increase in arthralgia score
at both follow-up visit 1 (P =0.010, estimate = -2.338 [95% CI, -4.104 to -0.572], Table
4.4) and follow-up visit 2 (P = 0.043, estimate = -2.588 [95% CI, -5.097 to -0.080, Table
4.4]). We did not find that CYP27B1 (rs4646536) was significantly associated with early
discontinuation of drug. We also did not find an association with VDR (rs11568820) and
the development of AI arthralgia or early discontinuation of drug
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Table 4.2 Vitamin D levels

Median (ng/ml)
Minimum (ng/ml)
Maximum (ng/ml)
Mean (ng/ml)
Standard Deviation
Deficient (n (%))
Insufficient (n (%))
Sufficient (n (%))

Baseline
(n = 196)
29.43
10.11
84.26
30.95
11.89
100 (51.0%)
85 (43.4%)
11 (5.6%)

Visit 1
(n = 188)
31.52
8.99
95.54
32.47
12.12
81 (43.1%)
91 (48.4%)
16 (8.5%)

Visit 2
(n = 145)
35.19
9.79
89.81
35.51
12.44
49 (33.8%)
79 (54.6%)
17 (11.4%)

Frequency < 25 (OH) D level
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100
Winter
Summer

75
50

6% Sufficient (>50ng/ml)
43% Insufficient (30-50ng/ml)
51% Deficient (<30ng/ml)

25
0
0

20

40

60

80

Time
Figure 4.2 Frequency distribution of patients' serum 25(OH)D levels
Levels of 25(OH)D were not significantly different during the winter (blue) than during
the summer (orange)
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P < 0.0001
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BMI (kg/m2)
Figure 4.3 Serum 25(OH)D is negatively associated with BMI
Effect estimate = -0.528, P < 0.0001. Solid line linear regression line; dotted lines 95%
confidence intervals. Statistical test: Linear regression model.
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Table 4.3 SNP information and genotyping quality control (n = 196)
SNP
location
MAF
or AA
in this
HWE
Gene
rs ID
change
Call rate
cohort
P value
VDR
rs11568820 Upstream
1.0
0.20
0.533
CYP27B1 rs4646536
Intronic
1.0
0.32
0.836
SNP single nucleotide polymorphism; MAF minor allele frequency; HWE Hardy–
Weinberg equilibrium
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Table 4.4 Genetic associations with change in AUSCAN and WOMAC score
AUSCAN
Gene
name
VDR

rs number
rs4646536

Follow-up
visit
1
2

Estimate
0.823
1.512

P value
0.438
0.486

95% CI
-1.268 to 2.915
-4.048 to 1.936

Sig.

-2.338
0.010
-4.104 to -0.572
1
*
-2.588
0.043
-5.097 to -0.080
2
*
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and
McMaster Osteoarthritis Index; CI confidence interval Sig. Significant. Statistical test:
logistical regression
CYP27B1

rs11568820

Table 4.4 continued
WOMAC
Gene
name
VDR

rs number
rs4646536

Follow-up
visit
1
2

Estimate
0.223
-0.334

P value
0.878
0.883

95% CI
-2.649 to 3.096
-4.830 to 4.162

Sig.

-1.759
0.159
-4.212 to 0.695
1
-2.083
0.281
-5.888 to 1.723
2
AUSCAN Australian/Canadian Osteoarthritis Hand Index; WOMAC Western Ontario and
McMaster Osteoarthritis Index; CI confidence interval Sig. Significant. Statistical test:
logistical regression
CYP27B1

rs11568820
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4.4 Discussion
In our study, patients with serum 25(OH) vitamin D level of greater than 50ng/mL were 4
times less likely to develop arthralgia. Previous studies have investigated this as a
potential intervention and have reported conflicting results. A double-blind placebocontrolled randomized study was performed with 60 women who were taking anastrozole
to establish whether vitamin D supplementation could improve the symptoms of AIinduced arthralgia. The study found that weekly high dose (50,000 IU) vitamin D
significantly improved musculoskeletal symptoms in patients on AIs [19]. A subsequent
study of 160 patients on a weekly dose of 30,000 IU of vitamin D did not demonstrate a
decrease in musculoskeletal symptoms [20]. In this study, patients in the vitamin D
treatment arm reached a median dose of 53.0ng/mL, [range = 25.2 to 81.0ng/mL] at week
12 and 64ng/mL (range 23.0 to 87.0ng/mL). There was a significant portion of the
treatment group that did not achieve 50ng/mL (>125nmol/l) levels on 30,000IU. It is
possible that a higher dose to ensure the 25(OH)D level is above 50ng/ml is required to
see a therapeutic effect. The patients in other studies which have found a positive effect
of vitamin D supplementation on AI arthralgia achieved serum 25(OH)D levels of greater
than 50ng/ml [21]. We found that CYP27B1 (rs4646536) was associated with an increase
in score on the AUSCAN scale, indicating worsening pain, stiffness, and physical
function in the hands, arms, and shoulders. We did not replicate previous findings by
Garcia-Gault that VDR (rs11568820) was associated with worsening musculoskeletal
symptoms. Furthermore neither SNP was associated with discontinuation of drug.
Vitamin D levels in our patients were not associated with either SNP, and 25(OH)D was
not a significant covariate when we added it into multivariable models with either of
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these SNPs. We did not observe a significant association between season and vitamin D
level, however this may be due to sample size. Several studies have identified a seasonal
impact on vitamin D level due to the changing levels of sunlight exposure, however these
studies need to be quite large in order to detect this effect [22]. In conclusion, our finding
suggest that sufficient vitamin D supplementation to reach a plasma level greater than
50ng/mL (>125nmol/l) could be a therapeutic strategy to help prevent AI arthralgia.
Further research is needed to establish the vitamin D dose that is required to consistently
produce this level in all patients, and to define other clinical variables, such as BMI,
which may influence vitamin D level.

110

4.5 References
1.

2.

3.

4.

5.
6.
7.
8.

9.

10.
11.

12.

13.
14.

15.

Coates, A.S., et al., Five years of letrozole compared with tamoxifen as initial
adjuvant therapy for postmenopausal women with endocrine-responsive early
breast cancer: update of study BIG 1-98. J Clin Oncol, 2007. 25(5): p. 486-92.
Baum, M., et al., Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for adjuvant treatment of postmenopausal women with earlystage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in
Combination) trial efficacy and safety update analyses. Cancer, 2003. 98(9): p.
1802-10.
Coombes, R.C., et al., A randomized trial of exemestane after two to three years
of tamoxifen therapy in postmenopausal women with primary breast cancer. N
Engl J Med, 2004. 350(11): p. 1081-92.
Borrie, A.E. and R.B. Kim, Molecular basis of aromatase inhibitor associated
arthralgia: known and potential candidate genes and associated biomarkers.
Expert Opin Drug Metab Toxicol, 2017. 13(2): p. 149-156.
Helde-Frankling, M. and L. Bjorkhem-Bergman, Vitamin D in Pain Management.
Int J Mol Sci, 2017. 18(10).
Zerwekh, J.E., Blood biomarkers of vitamin D status. Am J Clin Nutr, 2008.
87(4): p. 1087S-91S.
Capatina, C., et al., Vitamin d deficiency in postmenopausal women - biological
correlates. Maedica (Buchar), 2014. 9(4): p. 316-22.
Crew, K.D., et al., High prevalence of vitamin D deficiency despite
supplementation in premenopausal women with breast cancer undergoing
adjuvant chemotherapy. J Clin Oncol, 2009. 27(13): p. 2151-6.
Plotnikoff, G.A. and J.M. Quigley, Prevalence of severe hypovitaminosis D in
patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc, 2003.
78(12): p. 1463-70.
Singer, O., et al., Hypovitaminosis D is a predictor of aromatase inhibitor
musculoskeletal symptoms. Breast J, 2014. 20(2): p. 174-9.
Servitja, S., et al., Skeletal adverse effects with aromatase inhibitors in early
breast cancer: evidence to date and clinical guidance. Ther Adv Med Oncol,
2015. 7(5): p. 291-6.
Snijder, M.B., et al., Adiposity in relation to vitamin D status and parathyroid
hormone levels: a population-based study in older men and women. J Clin
Endocrinol Metab, 2005. 90(7): p. 4119-23.
Golzarand, M., et al., Vitamin D supplementation and body fat mass: a systematic
review and meta-analysis. Eur J Clin Nutr, 2018.
Kuchuk, N.O., et al., Relationships of serum 25-hydroxyvitamin D to bone
mineral density and serum parathyroid hormone and markers of bone turnover in
older persons. J Clin Endocrinol Metab, 2009. 94(4): p. 1244-50.
Garcia-Giralt, N., et al., Genetic determinants of aromatase inhibitor-related
arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat, 2013. 140(2): p.
385-95.

111

16.

17.

18.
19.

20.

21.

22.

Swenson, K.K., et al., Identification of tools to measure changes in
musculoskeletal symptoms and physical functioning in women with breast cancer
receiving aromatase inhibitors. Oncol Nurs Forum, 2013. 40(6): p. 549-57.
Bellamy, N., The WOMAC Knee and Hip Osteoarthritis Indices: development,
validation, globalization and influence on the development of the AUSCAN Hand
Osteoarthritis Indices. Clin Exp Rheumatol, 2005. 23(5 Suppl 39): p. S148-53.
Team, R.D.C., R: A language and environment for statistical computing (Version
3.3.1). 2016, R Development Core Team,: Vienna, Austria.
Rastelli, A.L., et al., Vitamin D and aromatase inhibitor-induced musculoskeletal
symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized
trial. Breast Cancer Res Treat, 2011. 129(1): p. 107-16.
Khan, Q.J., et al., Randomized trial of vitamin D3 to prevent worsening of
musculoskeletal symptoms in women with breast cancer receiving adjuvant
letrozole. The VITAL trial. Breast Cancer Res Treat, 2017. 166(2): p. 491-500.
Khan, Q.J., et al., Effect of vitamin D supplementation on serum 25-hydroxy
vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole
treatment for breast cancer. Breast Cancer Res Treat, 2010. 119(1): p. 111-8.
Bolland, M.J., et al., The effects of seasonal variation of 25-hydroxyvitamin D and
fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr, 2007. 86(4): p.
959-64.

112

5

DISCUSSION AND CONCLUSIONS
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5.1 Summary and Discussion
5.1.1

Chapter Four

The aromatase inhibitor letrozole is a first-line drug in the adjuvant treatment of breast
cancer in postmenopausal women. Adherence to AI therapy, including letrozole, remains
problematic due to the development of debilitating AI-associated arthralgia. Letrozole is
metabolized in the liver by CYP2A6. The aim of Chapter Four was to determine whether
plasma letrozole levels or CYP2A6 genetic variation is associated with the development
of arthralgia. We hypothesized that genetic polymorphisms in CYP2A6 were associated
with altered letrozole plasma levels and arthralgia.

More than half of patients experienced a significant increase in their arthralgia symptoms.
The clinical variables body mass index and age were negatively and positively associated
with plasma letrozole concentrations, respectively. CYP2A6 genotype was significantly
associated with letrozole levels and increased plasma letrozole levels were observed in
patients with CYP2A6 reduced-function genotypes. We found that letrozole drug level
and CYP2A6 genotype were not significantly associated with a change in pain score from
baseline. From our studies, we demonstrate that letrozole concentration is not responsible
for the development of AI arthralgia. A prospective study of patients on exemestane and
letrozole did not detect differences between steady-state drug concentrations and patientreported quality of life outcomes or treatment discontinuation [1]. Though maintaining
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systemic drug concentrations within a therapeutic range is essential for some drugs, this
does not appear to be the case for AIs.

5.1.2

Chapter Five

Female patients with breast cancer develop arthralgia when treated with AIs. Though the
mechanism of AI arthralgia is unknown, clinical factors and potential biomarkers have
been identified that may predict their development. Replication and validation of these
biomarkers are an essential next step to move these discoveries into implementation in
patient care. The aim of this chapter was to investigate the clinical and genetic predictors
of AI arthralgia in a prospective cohort of patients with estrogen receptor-positive breast
cancer. We hypothesized that SNPs previously identified by genetic screens and genomewide association studies would be significantly associated with arthralgia and early
discontinuation of therapy in our population.

Of the 196 women, more than 50% experienced arthralgia symptoms. Genetic analysis
revealed that four SNPs, in CYP19A1 (rs4775936) and ESR1 (rs9322336, rs2234693,
rs930799), were associated with the development of arthralgia. BMI was also associated
with the development of arthralgia symptoms compared to baseline. Patients prescribed
letrozole were significantly more likely to develop arthralgia than patients on anastrozole,
and also more likely to discontinue AI therapy due to arthralgia. One SNP, in CYP19A1
(rs4775936), and BMI were significantly associated with discontinuation of drug due to
intolerable arthralgia.
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Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical
predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and
rs930799 were the genetic predictors of AI arthralgia. Significantly, rs4775936 is also a
predictor of discontinuation of drug.

5.1.3

Chapter Six

In Chapter Six, we hypothesized that the vitamin D pathway played a vital role in the
development of arthralgia. The aim of this chapter was to attempt a replication of
previously identified genetic predictors of AI arthralgia. We hypothesized that genetic
variants in the vitamin D signalling and metabolism pathway and serum 25hydroxyvitamin D [25(OH)D] levels contribute to the development of AI arthralgia in
patients with ER-positive breast cancer. We found that a SNP in CYP27B1 previously
identified in a candidate gene study was significantly associated with of pain, stiffness,
and worsening physical functioning in the hands, arms, and shoulders. We also found
evidence suggesting that a [25(OH)D] level of 50ng/ml or greater is protective against the
development of AI arthralgia.

5.2 Therapeutic Interventions
To our knowledge, this is the first data set of its kind to prospectively measure AIarthralgia using the AUSCAN and WOMAC, while also collecting genotypic, clinical,
and drug level data in patients on AIs. Our studies revealed that the AUSCAN and
WOMAC were sensitive measures of AI arthralgia. The use of the AUSCAN and the
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WOMAC may be applied in clinical practice to help clinicians assess patient
musculoskeletal symptoms.
In addition, we demonstrated that a serum 25(OH)D level of 50ng/ml was the threshold at
which the patients were 4 times less likely to develop AI arthralgia. Combined with
findings from other vitamin D randomized clinical trials [2, 3], these data support vitamin
D supplementation as an intervention to try to prevent AI arthralgia. Next steps could
include a vitamin D randomized clinical trial with the goal of achieving at least 50ng/ml
serum 25(OH)D level.

5.3 Limitations
We were enrolling patients from one hospital site in London, Ontario. This meant that our
patient population predominantly Caucasian and we were somewhat limited in our
sample size. Though we enrolled sufficient patients based on our power calculations, it
would be interesting to include a greater number of patients in the future.
Enrolling patients in a busy clinic environment meant that it was not feasible to conduct
an extensive battery of tests that may measure different aspects of arthralgia. Because of
this, we selected previously validated questionnaires to measure pain, stiffness, and
physical functioning. However, a limitation is that we could have used other measures,
such as a 6-minute walk test and grip strength tests to measure arthralgia in our patients.
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5.4 Future Directions
Collaborating with other Canadian, U.S., and international cancer centers would allow us
to expand the study population and examine more patients from different ethnic
backgrounds.
Other future studies could employ the use of a greater number of assessments in order to
measure pain, stiffness, and physical functioning in patients in addition to the AUSCAN
and WOMAC questionnaires. The 6-minute walk test or grip strength test could be added
in order to further measure arthralgia in our patients. Previous studies have utilized
magnetic resonance imaging (MRI) of hands and wrists to measure tenosynovial changes
and intra-articular fluid in patients with AI induced arthralgia [4]. If more funding were
available, it would be interesting to perform MRI on the hands, wrists, and other joints at
baseline and follow-up appointments.
It is essential that we have a better understand the mechanisms underlying the
associations with SNPs identified in our studies. Further in vitro investigations of
estrogen metabolism and estrogen signalling could help to better understand the
mechanism underlying AI arthralgia.

5.5 Conclusions
There is a growing recognition of the role of genetic factors in the development of
adverse drug reactions and that genetic variability can predict drug response. The focus of
this thesis was aromatase inhibitors, an important group of endocrine therapy drugs used
to treat breast cancer in post-menopausal women. We focused on validating previously
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identified molecular and genetic biomarkers. We also examined the role of different
pathways that underlie the mechanism of AI arthralgia. Taken together, these studies
increase our understanding of AI arthralgia and improve our ability to predict variability
in the pharmacokinetics of and response to aromatase inhibitors.
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Appendix C - Australian Canadian Osteoarthritis Hand Index
AUSCAN Survey

ID Number:

Instructions: In Sections A, B, and C, questions will be asked about your shoulder, arm or hand pain. Please mark each
response with an X. If you are unsure about how to answer a question, please give the best answer you can.
A. Think about the pain you felt in your shoulders/arms/hands during the last 48 hours.
Question: How much pain do you have?
None
Mild
Moderate Severe Extreme

1. At rest
2. Gripping objects with your hands
3. Lifting objects
4. Turning objects
5. Squeezing objects
B. Think about the stiffness (not pain) you have in your shoulders/arms/hands during the last 48 hours. Stiffness is a sensation
of decreased ease in moving your joint.
None
Mild Moderate Severe Extreme
6. How severe is your stiffness after first awakening in the morning?

C. Think about the difficulty you had in doing the following daily physical activities due to your shoulders/arms/hands during the
last 48 hours. By this we mean your ability to move around and look after yourself.
Question: What degree of difficulty do you have?

7. Turning tap/faucets on
8. Turning a round doorknob or handle
9. Doing up buttons
10. Fastening jewelry
11. Opening a new jar
12. Carrying a full pot with one hand
13. Peeling vegetables/fruits
14. Picking up large heavy objects
15. Wringing out wash cloths

None

Mild

Moderate Severe Extreme
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Appendix D - Western Ontario and McMaster Universities Arthritis Index
WOMAC Survey

ID Number:

Instructions: In Sections A, B, and C, questions will be asked about your hip or knee pain. Please mark each response with an
X. If you are unsure about how to answer a question, please give the best answer you can.
A. Think about the pain you felt in your hip/knee during the last 48 hours.
Question: How much pain do you have?
None

Mild

Moderate Severe Extreme

1. Walking on a flat surface
2. Going up and down stairs
3. At night while in bed, pain disturbs your sleep
4. Sitting or lying
5. Standing upright
B. Think about the stiffness (not pain) you have in your hip/knee during the last 48 hours. Stiffness is a sensation of decreased
ease in moving your joint.
None
Mild Moderate Severe Extreme
6. How severe is your stiffness after first awakening in the morning?
7. How severe is your stiffness after sitting, lying, or resting in the day?

C. Think about the difficulty you had in doing the following daily physical activities due to your hip/knee during the last 48 hours.
By this we mean your ability to move around and look after yourself.
Question: What degree of difficulty do you have?

8. Descending stairs
9. Ascending stairs
10. Rising from sitting
11. Standing
12. Bending to the floor
13. Walking on flat surfaces
14. Getting in and out of a car, or on or off a bus
15. Going shopping
16. Putting on your socks or stockings
17. Rising from the bed
18. Taking off your socks or stockings
19. Lying in bed
20. Getting in or out of the bath
21. Sitting
22. Getting on or off the toilet
23. Performance heavy domestic duties
24. Performing light domestic duties

None

Mild

Moderate Severe Extreme
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